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Trypanosome Lytic Factor (TLF) is an innate immunity complex that was originally 
discovered to protect against African Trypanosomes. The major components of TLF are 
Apolipoprotein A1 (APOA1), Apolipoprotein L1 (APOL1) and HPR (Haptoglobin Related 
Protein), where APOL1 is necessary and sufficient for trypanolysis. Recently we have shown 
that TLF ameliorates infections by cutaneous Leishmania species. Here we investigated the 
effect of different primate and human TLF against different Leishmania sp. Our result shows 
that TLF kills metacyclic promastigotes of cutaneous Leishmania sp. within immune cells 
such as neutrophils and macrophages by two different mechanism.  
Using transiently transfected and germline transgenic mice, we show that baboon as well as 
human TLF is effective at protecting against cutaneous Leishmania sp. that depends on TLF 
as well as infectivity dose. We found neutrophils are important for this TLF mediated 
immunity where TLF activity initiates in acidic phagosome of neutrophils leading to lysis of 
the metacyclics when they are released in the extracellular milieu. We also investigated the 
effect of TLF against parasite in macrophages. Using our in vitro assay that ostensibly 
mimics macrophage phagosome and parasitophorous vacuole, we show that TLF mediated 
lysis of metacyclics also occur when there is gradual acidification in maturing phagosome. 
However, proliferating parasites such as metacyclics of visceral strains and amastigotes of 
cutaneous strains are resistant to TLF activity. This resistance possibly depends on surface 
glycoproteins as glycosylation deficient mutants are resistant to TLF.  
In conclusion, our results show that TLF is an important immunity complex that synergize 
with immune cells like neutrophils and macrophages to kill metacyclics of cutaneous 
Leishmania sp.  
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1. High-density lipoproteins  
a. Structure and composition 
High-density lipoproteins (HDL, the good cholesterol) are small and dense lipoproteins circulating in 
our blood. HDL is made up of core of lipids that is comprised of triglycerides, cholesterol, cholesteryl 
ester and an outer phospholipid layer that embeds proteins and microRNAs [1]. The protein 
components, also called apolipoproteins, make up approximately 50% of the mass of HDL [2-4]. Of 
more than 80 different apolipoproteins, which govern the heterogeneous nature of HDLs, 
Apolipoprotein A-I (apoA-I) is the major protein that forms the structural backbone of the HDL. ApoA-I 
is secreted from the liver and the intestine and concomitantly lipidated to form HDL particles due to the 
activity of ATP binding cassette transporter A1 (ABCA1)[5]. Initially upon secretion apoA-I is in a belt 
like arrangement and starts accepting lipid to form nascent HDL that subsequently becomes discoidal, 
pre-β HDL. A plasma enzyme called Lecithin:cholesterol acyl transferase (LCAT) then esterifies the 
cholesterol into cholesteryl ester thereby increasing the lipidation of the HDL to form mature spherical 
HDL [6]. Upon transitioning from the nascent to mature form, there may be between 1 and 5 apoA-I 
molecules per HDL particle, where the alignment of apoA-I ranges from belt like in nascent HDL to 
trefoil or tetrameric or pentameric in mature spherical HDL [7]. These mature HDLs are named as 
HDL3, and HDL2, where HDL2 is the larger HDL than HDL3. Each type of HDL is further divided into 
subtypes as shown in Figure 1. Therefore, we observe heterogeneity in size, shape, density and 
charge of circulating HDL based on its lipid to protein ratio and the stage of maturity. This 
heterogeneity forms the basis of separation and analysis of HDL by various techniques such as 
ultracentrifugation, gel filtration, sizing, electrophoresis, and nuclear magnetic resonance spectroscopy 











Figure 1: HDL classification based on size and density 
HDL can be classified based on its shape as A. discoidal or B. spherical. It can also be classified 
based on its C. size or density in which HDL3c is the smallest and the densest complex while HDL 2b 
is the largest and the least dense HDL. Source: Annema and Eckhardstein, 2013.  
 
b. Function 
I. Reverse Cholesterol transport 
One of the important functions of HDL is to transport cholesterol from peripheral cells to the liver or 
intestine for excretion by a process called reverse cholesterol transport. Cholesterol efflux is the first 
step in the reverse cholesterol transport. The transport of cholesterol from peripheral cells and 
macrophages to the acceptor such as apoA-I or HDL occurs by four different pathways:  
a) After HDL synthesis and secretion from the liver and intestine, apoA-I accepts the lipids from 
cells mediated by the ABCA1 receptor. This process leads to the formation of nascent HDL 
that is discoidal in shape [5] Fig 1A.  
b) Another important pathway of cholesterol efflux from cells into HDL is by passive diffusion, 
which is facilitated by the activity of LCAT, which esterifies the cholesterol and moves it to the 
core and thereby prevents the influx of released cholesterol back into the cells [9, 11, 12]. 
c) Macrophages and some other cells express another receptor called the ATP binding cassette 
transporter G1 (ABCG1), which is responsible for the efflux of cholesterol from cells into HDL 
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d) Scavenger receptor class B type I (SR-BI) is another receptor that is ubiquitously distributed in 
the cells in our body and is responsible for the bidirectional flux of cholesterol including the 
efflux of cholesterol into the mature HDL particles [15]. 
The effluxed cholesterol that is carried within HDL due to the esterification of cholesterol by the activity 
of LCAT is then carried to the liver. In the liver, the uptake of cholesterol can occur due to the activity 
of the SR-BI that selectively uptakes the cholesteryl esters into liver [16]. Alternately, HDL can be 
taken up into liver cells by holoparticle endocytosis that is mediated by the F(1)-ATPase/P2Y pathway 
[17] . Finally, cholesteryl ester transfer can happen from HDL into apolipoprotein B (apo B)- containing 
lipoproteins due to the activity of Cholesterol Ester Transfer Protein (CETP). These acceptor 
lipoproteins are then removed from circulation by the activity of LDL receptors on the hepatocytes[18]. 
The cholesterol is then removed from the liver by excretion into bile as bile acids or as free cholesterol. 
II. Anti-oxidation 
The anti-oxidative properties of HDL have been attributed to its different components such as apoA-I, 
paraoxanase-1 (PON-1), phospholipase-A2 and LCAT. Oxidation of plasma low-density lipoprotein 
(LDL) is harmful as it produces pro-atherogenic lipoprotein particles that can deposit on endothelial 
walls. This oxidation of LDL can be overcome by the anti-oxidative property of HDL [8]. 
III. Anti-inflammatory 
Atherosclerosis is the consequence of a pro-inflammatory response that results in the up regulation of 
adhesive factors in the endothelial lining giving rise to plaque. This process begins from the oxidation 
of the lipoproteins and other components from the endothelial lining of a developing atherosclerotic 
plaque. The anti-inflammatory property of HDL aids in moderation of this process under normal 
conditions, which is perturbed under disease conditions. The HDL anti-oxidative components such as 
PON-1 and LCAT are known to reduce the production of pro-inflammatory cytokines such as tumor 
necrosis factor- alpha, interleukin-1, monocyte chemotaxis protein-1 etc by endothelial cells and 
smooth muscles [19, 20].  
IV. Role of HDL in infections 
HDL possibly has an important role in different infections, as many infections are associated with 
dyslipidemia and the alteration in the size and composition of HDL. For example low plasma HDL-C 
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has been found to be associated with the severity of acute bacterial infections such as septicemia and 
parasitic infections such as visceral leishmaniasis [21, 22]. Likewise low levels of APOA1, the 
canonical protein of plasma HDL has been associated with the severity of septicemia [23]. On the 
contrary, overexpression of APOA1 in septic mice is associated with survival [24]. These observations 
suggest that HDL has an important role in the protection against these infections. 
APOA1 is not the only HDL component associated with protection against different infections. Another 
HDL protein, apolipoprotein L1 (APOL1) has also serves as an innate immune component against 
different infections. Originally discovered due to its protective role against African Trypanosomes [25-
27], APOL1 has been recently been associated with protection against other disease agents such as 
Leishmania sp. and Human Immunodeficiency Virus (HIV) [28, 29]. APOL1 is the component of a 
specialized HDL sub-complex known as Trypanosome Lytic Factor (TLF), named due to its ability to 
lyse African trypanosomes. 
2. African Trypanosomes 
a. The disease and its distribution 
African trypanosomes are the causative agents of human African trypanosomiasis (HAT) also called 
African sleeping sickness in humans. Some parasites in this group also cause animal infections in wild 
and domestic animals. The disease is called animal African trypanosomiasis (AAT). When the disease 
affects cattle it is commonly called Nagana. Although the human infection occurrence has dropped 
significantly over recent years, African trypanosomiasis in cattle presents a huge economic burden in 
affected regions [30]. 
The parasites causing African trypanosomiasis in humans and animals belong to order Kinetoplastida, 
genus Trypanosoma. In general Trypanosoma brucei subspecies are called African Trypanosomes. 
These parasites can be further subdivided into three morphologically similar sub-species; T. b. brucei, 
T. b. rhodeseinse and T. b. gambiense. T. b. brucei causes trypanosomiasis in animals while T. b. 
rhodesiense and T. b. gambiense are human infective forms [31]. The disease is usually transmitted to 
the vertebrate host after a bite by infected tsetse fly. Therefore, the disease occurrence is goverened 
by the existence of the tsetse in the region. In addition to the vector transmission, it is rarely 
transmitted trans-placentally from mother to child or due to sexual contact, when blood is exchanged. 
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As reported by WHO the disease is also mechanically transmitted by blood sucking tabanids and has 
thus spread out of Africa.  
According to “The Cattle Site” animals in 37 African countries are affected by Nagana that covers 10 
million square kilometers [32]. The disease is characterized by acute onset of disease within 24 days 
of infection that leads to fever, edema, anemia, loss of appetite and oftentimes causes abortion in 
animals. Eventually the animals become emaciated and show digestive and neurological dysfunction 
leading to death in chronic disease. Some acute disease may also lead to early death of the animals 
[32]. Therefore, it is a huge economical burden in the affected areas as infected animals are wasted 
and hence are not suitable for meat or milk. In addition, the disease also affects the fertility of the 
animals making it a devastating livestock disease. 
The Human African Trypanosomiasis (HAT) is commonly distributed in sub-saharan Africa. It is 
caused by T. b. rhodesiense in Southern and Eastern Africa and by T. b. gambiense in central and 
West Africa. Uganda is the only country in Africa that has both forms [33]. The disease caused by T. b. 
rhodesiense is also called Eastern sleeping sickness and represents 3% of the total HAT reported. 
Most of these cases are from Malawi, Tanzania, Uganda, and Zambia. Apart from humans T. b. 
rhodesiense also infects wild and domestic animals, which serve as the reservoir for the transmission 
of the disease. In humans, the disease by T. b. rhodesiense is usually characterized by acute onset. 
The first sign of disease is observed few weeks to months after the first infection. Eventually the 
patient develops neurological symptoms when the parasite reaches the brain crossing the blood-brain 
barrier. In this stage, the sleep pattern of the patient is disrupted, hence the name “The sleeping 
sickness”. If untreated death occurs within months [31]. 
Another parasite causing sleeping sickness in humans is T. b. gambiense, which causes 
approximately 97% of the total HAT reported [31]. There are two group of these parasites named 
Group I and Group II T. b. gambiense. One of the major differences between the two is their virulence. 
The Group I Gambiense are the most prevalent type and are invariably resistant to human serum  
(TLF) while the Group II Gambiense loose their serum resistance property upon continuous passage 
in mice and can regain resistance upon passage in human sera (TLF). The disease caused by T. b. 
gambiense is mostly prevalent in Angola, Democratic Republic of Congo (DRC), South Sudan, Central 
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African Republic and Uganda [34]. Approximately 90% of the cases of HAT due to T. b. gambiense 
are from DRC [34]. Because of the distribution of the disease in Central and West Africa, it is often 
called the West African sleeping sickness [35]. The disease is chronic characterized by slow 
progression. Initial infection may be characterized by mild symptoms such as headaches, fever, joint 
and muscle pains, and swollen lymph nodes. At this stage, the parasitemia in patient blood is typically 
low making it complicated to diagnose the disease. After 1-2 years of initial infection or 3 years in 
some case, the patients develop neurological symptoms characterized by personality changes, 
confusions, and sleep dysregulation. Because of its chronic onset, the disease is often diagnosed in 
the late stage leading to high mortality and morbidity.  For the same reason, humans account for major 
carriers of the parasites and hence the disease is anthroponotic. Although few domestic and wild 
animals can get infected with T. b. gambiense [31, 34], its epidemiological role is not extensively 
studied yet. 
b. Parasites and Life cycle 
Trypanosomes are unicellular, flagellated, extracellular parasites that are transmitted to humans and 
animals by a vector called Tsetse fly (Fig 2). However, other forms of transmission such as mother to 
fetus or mechanical transmission by blood sucking insects, sexual transmission and needle inoculation 
may transmit the disease in rare cases [30].  
After the bite, the parasite makes its way from subcutaneous tissue into blood and lymph. This stage is 
easier to manage and is characterized by symptoms such as headache, fever, joint pains and itching. 
The first stage is followed by a neurological stage where the parasite crosses the blood-brain barrier 
and infects central nervous system. In this stage, the patient presents neurological symptoms and 
changes in behavior, confusion, sensory disturbances, poor coordination and disturbances of sleep 
cycle, which gives its name sleeping sickness. It is difficult to treat patients when they have 
progressed to the neurological stage. Drugs such as Melarsoprol, Eflornithine, and Nifurtimox manage 
this stage. These drugs are toxic and difficult to administer which complicates the treatment of the 
disease at this stage [30]. Therefore, it is important to study the basic biology of the parasite and its 







Figure 2: Life Cycle of African Trypanosomes  
The parasites are injected into the host during its blood meal. Once in the blood the parasites 
transform into trypomastigote stage in the bloodstream. These trypomastigotes multiply and invade 
different places.  The trypomastigote in the blood are then taken up by another tsetse during its blood 
meal and transform into procyclic trypomastigote in tsetse fly midgut which undergo transformation to 
form epimastigotes in the salivary gland and the cycle continue when this fly bites a healthy host 
during its blood meal. [35] 
Source: CDC.gov.  
 
c. Parasite morphology and immune evasion 
Members of T. brucei are unicellular parasites with a single flagellum that originates from its flagellar 
pocket and runs along the length of parasite to protrude out from the cell body. This flagellar pocket is 
marked by an invagination and is devoid of the microtubule scaffold that is present throughout the cell 
body of the parasite. Therefore, this flagellar pocket is the place for the entry and exit of nutrients and 
other transfered materials [36]. At the base of this flagellar pocket is a structure known as basal body, 
which has the kinetoplast in its proximity. The parasites also contain a single nucleus, mitochondrion, 
golgi and lysosome. These core structures are supported by the microtubule skeleton, which is 
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covered with 15nm thick surface coat proteins called Variant Surface Glycoproteins (VSGs) [37]. VSG 
comprises 95% of the surface proteins of trypanosomes [38]. They are glycosylphospoinositol (GPI) 
anchored proteins and are expressed from genes called Variant Surface Glycoprotein (VSG), which 
are located at the telomeric regions of the parasites’ chromosomes. A host immune system can 
effectively recognize and clear these VSG on the extracellular trypanosomes. However, the presence 
of many VSG genes, which switch continuously leading to antigenic variation, provide an advantage to 
the parasites to survive in the host by evading the host immune system. This antigenic variation in 
trypanosomes is more complex than a single changed coat due to the switching of the VSG repertoire. 
According to the recent study by Mugnier et al, at any point of time during infection, there are several 
(as many as hundred) different VSGs expressed by individual parasites in a population along with 
recombinant VSGs called mosaics formed due to complex gene conversion events [39]. Thus the 
parasites have ability to form large repertoire of VSGs. The VSG coat is highly immunogenic. As a 
result they evoke strong antibody response that then destroy the parasites due to complement 
deposition or phagocytosis. Some parasites are able to change their coat to new VSG and evade 
immune detection. These parasites with new coat then grow in the blood until it is destroyed by the 
antibody response when another with a different coat come and this process continues. Thus 
parasites easily disguise themselves from recognition and destruction by host antibody mediated 
immunity. Since adaptive immunity is not sufficient to fight these parasites, hosts such as humans and 
higher primates have evolved to develop an innate immunity factor to fight trypanosomes. It is called 
Trypanosome Lytic Factor (TLF) due to its ability to lyse trypanosomes. Due to the presence of TLF, 
human serum is cytotoxic to animal infective T. b. brucei. Human infective forms such as T. b. 
rhodesiense and T. b. gambiense are however, resistant to the cytoxic effect of human sera, as they 
have evolved to evade the TLF mediated lysis [40].  
The resistance in T. b. rhodesiense is due to the expression of a VSG family protein called Serum 
Resistance Associated Factor (SRA) [41]. This GPI anchored protein localizes intracellularly in the 
parasite endocytic vesicles, lysosome, and flagellar pocket [42, 43]. Using His-tagged SRA and alexa-
labelled APOL1, Vanhamme et al, showed colocalization of the two proteins in the endocytic 
compartments and lysosomes [27]. In separate study using surface plasmon resonance and the C-
 
! 9!
terminal domain of the APOL1 protein, Thomson and Genovese et al, have shown that the interaction 
between the two proteins is pH dependent with maximum affinity at pH 4.5 [44]. However, labeled 
TLF1 is not found in the lysosomes of parasites expressing SRA in the absence of lysosomal protease 
inhibitors like FM464 [42, 45]. These data suggest that SRA interacts with C-terminus of APOL1 in the 
acidic endosome/lysosome leading to the proteolysis of the APOL1/TLF complex within the lysosome 
thereby inhibiting its trypanolytic activity.  
TLF resistivity in Group I T. b. gambiense is due to a mutation in the receptor TbHpHbR that is 
required for the uptake of the parasites [46]. Because of the mutation in the receptor there is reduced 
uptake of TLF in these parasites. In addition, these parasites also express a truncated VSG called 
TgsGP. TgsGP has been proposed to stiffen the parasite membrane and contribute to resistance the 
to TLF [47, 48].  
3. Trypanosome Lytic Factor (TLF) 
a. TLF is specialized HDL 
For many years, humans’ and some primates’ sera were known to have a toxic effect against animal 
infective trypanosomes. Rifkin for the first time showed that high density lipoprotein is the actual lytic 
factor of these animal infective trypanosomes [49].  Due to its activity against the African 
trypanosomes this high-density lipoprotein got its name Trypanosome Lytic Factor (TLF). TLF are 
specialized HDL that can be subdivided into two sub-fractions namely TLF1 and TLF2. TLF1 does not 
fall into the classical HDL nomenclature, because it is large and dense [50] with approximately 60% 
protein and 40% lipid. TLF1 is approximately 500kDa in size and is made up of APOA1, the canonical 
HDL structural protein along with two unique proteins Apolipoprotein L1 (APOL1) and Haptoglobin 
related protein (HPR) [51-53]. TLF2 on the other hand is a lipid poor pre-beta complex that is 1000 
kDa in size. The major components of TLF2 are APOA1, APOL1, HPR and IgM [53, 54].  
b. Subcomponents of TLF 
I. Haptoglobin Related Protein (HPR) 
The unique components that give lytic property to the TLF complex are APOL1 and HPR [26, 27, 30, 
54-57]. Of these components, HPR named due to its similarity to haptoglobin (HP), has 91% sequence 
homology to the HP [55, 58]. HP and HPR are expressed from the haptoglobin gene cluster. This 
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gene cluster arose due to the result of gene triplication of HP locus followed by deletion of one copy 
after the split of Old World Monkeys (OWM) and New World Monkeys (NWM) (Fig 3) [59].   
HPR is a 45kDa protein with a signal peptide that is retained in the mature secreted protein, which 
makes HPR unusual among secreted proteins. Currently there are two other proteins known to retain 
their signal peptide in the mature secreted proteins namely: paraoxanase-1 (PON1) and 
apolipoprotein M (apoM). Interestingly, all three proteins HPR, PON1, and APOM are components of 
HDL complexes [60, 61]. The retained signal peptide is essential for the proteins to associate with the 
HDL complex [60-62]. Although lipid alone is sufficient for HPR to associate with Large Unilamellar 
Vesicles (LUV), Harrington et al., have shown that presence of APOL1 enhances the binding of HPR 
to the LUV [62]. Hence, APOL1 may enhance the association of HPR to TLF or membranes when it is 
secreted from cells. Lipidated HPR has been shown to have higher affinity for its co-factor hemoglobin 
as compared to HPR alone [62]. Therefore the property of HPR is affected by other components of 
TLF. Despite the high degree of structural similarity with HP and its ability to bind to hemoglobin, HPR 
has some structural differences with HP including the retention of signal peptide in HPR, which is 
removed in HP. Like HP, HPR is expressed as a nascent peptide that is eventually cleaved into two 
fragments to form alpha and beta subunits. A disulfide bridge holds the alpha and beta subunits 
together. Two alpha-subunits then interact with each other to form a tetramer made of two alpha and 
two beta subunits. Thus the structural organization of HP and HPR at the molecular level are very 
similar. However, the alpha-chain of haptoglobin has a cysteine residue at position 33 that is absent in 
HPR. The extra cysteine residue gives an additional disulfide bridge between two alpha subunits and 
hence more stability in HP, which is absent in HPR [63]. The most striking difference in sequence is 
however in the beta subunit. Four amino acids in HPR at valine 259, glutamate 261, lysine 262 and 
threonine 264, makes it unrecognized by CD163, the human haptoglobin-heamoglobin receptor found 
on macrophages and monocytes. This makes HPR functionally different from HP because the high 
affinity binding of haptoglobin bound hemoglobin to CD163 is responsible for the receptor mediated 
clearing of HP-HB complexes by macrophages and monocytes during hemolysis [63]. For the same 




Despite these differences, the structural similarity between HPR and HP is exploited by our immune 
system to combat against extracellular parasites African trypanosomes. African trypanosomes are 
heme auxotrophs and have a receptor called Trypanosoma brucei haptoglobin-hemoglobin receptor 
(TbHpHbR) to scavenge haptoglobin bound hemoglobin that serves as a source of heme for the 
parasites [64]. Knocking out this receptor in parasites makes trypanosomes less sensitive to lysis by 
TLF containing serum implying that the receptor helps in uptake of TLF [64, 65]. The disadvantage of 
structural similarity between HPR and HP comes from the fact that plasma haptoglobin when bound to 
heamoglobin can competitively inhibit the binding of HPR-HB to the trypanosome receptor and hence 
inhibit TLF activity [66]. This inhibition is however, specific to TLF1. In contrast to TLF1, presence of or 
variation in haptoglobin levels does not affect TLF2 activity [67].  In serum the level of HPR is 0.03-
0.04 mg/ml, which is 10 fold lower than that of HP (0.27-1.39 mg/ml) [68]. Therefore, TLF1 is always 
inhibited in normal human serum and only active upon extensive hemolysis when all the HP-HB 
complexes are completely cleared. Thus, TLF2 is considered more relevant than TLF1 to protect 


















Figure 3:  The Haptoglobin Gene locus 
The haptoglobin gene locus underwent triplication after split of the OWM and NWM to form the hp, hpr 
and hpp. Therefore, in primates there are haptoglobin, haptoglobin related protein and haptoglobin 
primate protein gene locus.  In human the triplication event was followed by a deletion event that lead 
to the deletion of hpp and therefore humans have hp and hpr gene in the cluster. 















II. Apolipoprotein L1 (APOL1) 
Apolipoprotein L1 is a 42 kDa pore forming protein. It is an important component of TLF complex, 
which is necessary and sufficient for trypanolysis [26, 27]. The protein structure has not been resolved 
due to the fact that the protein is not crystallized.  There are different structures predicted for the 






Figure 4: APOL1 predicted domains with five common haplotypes.  
APOL1 is a secreted protein that has 27 aa long signal peptide. It has a predicted N-terminal domain, 
three transmembrane domains and a C-terminal coiled coil domain. The backbone shown above 
represents the most common haplotype, G0, present in 80% of the population. African haplotypes are 
G1 (p.S342G and p.I384M), G2 (p.delN388/Y389) and G3 (pK255R). G4 (p.I228M, K255R) is the 
neanderthal APOL1 retained in 22% modern Europeans, 20% Asians and 11% South Americans. 
 
The mature protein is 398 amino acids long and contains a 27 amino acid long signal peptide [50]. 
Due to the presence of the signal peptide, APOL1 is secreted and hence can be assembled in HDL 
particles. Due to weak homology of the APOL1 protein to bacterial colicins, the N-terminal 60-235 
amino acids were believed to be essential for pore formation by APOL1 based on its ability to kill 
bacteria in vitro. It was therefore hypothesized that C-terminus of the protein was dispensable for the 
lytic activity of the protein [27, 69]. However, later studies have established that C-terminus of the 
protein is essential for the trypanolytic activity of APOL1 [26, 69].   
APOL1 is predicted to have a putative BH3 motif [70, 71], which is not essential for trypanolysis or 
pore formation by APOL1. This was shown by mutating the core BH3 motif amino acids in the protein 
to alanine, the APOL1 was still toxic when expressed in Xenopus Oocytes as well as trypanolytic to 
trypanosomes in vivo in transient transgenic mice expressing the mutant APOL1 [72]. In addition to 
this Bcl2 domain, there are three predicted transmembrane domains, which are required for the 




characterized. Finally, the C-terminal domain of APOL1 has been shown to bind to the serum 
resistance associated (SRA) protein of human infective T. b. rhodesiense at low pH and hence is also 
called the SRA interacting domain. [44, 69]. The difference in APOL1 sequences of OWMs including 
baboons to that of humans at the C-terminus makes them lytic to T. b. rhodesiense suggesting that 
this domain is important for the neutralization of APOL1 by SRA. Moreover, deletion of the C-terminus 
of APOL1 leads to loss in its ability to form pores in bilayers and lyse African trypanosomes [26]. 
Therefore, this domain is essential for APOL1 mediated pore formation and lysis.  
• APOL1 lyses cells by forming a pH dependent cation selective pore  
Trypanosomes are auxotrophs of heme. To access heme, trypanosomes have a haptoglobin 
haemoglobin (HPHBR) receptor, thus TLF can piggyback on this receptor by HPRHB dependent 
receptor mediated uptake via the TbHPHBR. In addition, TLF can be endocytosed by yet unknown 
scavenger receptor and also by pinocytosis [73]. Once in an acidic endocytic compartment, APOL1 
will lyse the parasites due to pore formation, followed by colloidal osmosis. The acidic pH is essential 
for this APOL1 mediated lysis, which can be blocked by neutralizing the acidic endosomes with weak 
bases such as ammonium chloride (NH4Cl) and chloroquine [74].  Osmotic agents such as sucrose 
can also inhibit the cellular swelling and lysis, suggesting that influx of water leads to the lysis of the 
parasites [25]. Finally substitution of Na+ ions (the most abundant ion in extracellular fluid) with large 
cations such as tetramethylammonium+ or Choline + or chloride with anions such as gluconate delays 
the lysis by APOL1 suggesting that the formation of ionic pores are in the plasma membrane of the 
parasites [25, 56]. The delay due to the replacement of sodium by larger cations happens if the 
substitution is done at the time of incubation with TLF. After 60 minutes, the replacement of sodium 
does not prevent the lysis, because the cations have already equilibrated across the plasma 
membrane. At this time (i.e. 60 minutes post incubation with TLF), lysis can be delayed by substituting 
chloride with large anions [25]. These observations suggest that TLF forms pore that initially allows the 
selective influx of sodium, which changes the membrane potential by reducing the negative charge 
inside the cell. Chloride channels then open and flux of chloride increases the negative membrane 
potential. However, the increase in ions inside the cell drives water through aquaporins that leads to 
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the swollen morphology and lysis. Infact, TLF was shown to form cation selective pores at pH 5.5 in 
the lipid bilayer extracted from the parasites [25]. 
TLF mediated lysis can be observed by incubating the parasite with recombinant APOL1 alone. 
However, the kinetics of lysis by APOL1 is much slower than that by TLF [25, 27, 56]. It could be due 
to the fact that APOL1 has to rely on pinocytosis- mediated uptake as compared to the receptor 
mediated endocytosis of TLF [73]. The APOL1 mediated pore formation is observed in lipid bilayers as 
well where the protein associates with membranes in acidic pH (5.3) as observed by a small increase 
in membrane conductance when APOL1 is added to the cis/extracellular/luminal side at pH 5.3 
(trans/cytoplasmic side at pH 7.2) [75]. A small increase in conductance also implies that ions can 
slowly leak through due to the association of APOL1 with the membrane. However, upon increasing 
the pH of the cis/extracellular/luminal side to 7.4 the conductance drastically increases, indicative of a 
pH gated channel. These observations can be explained in the context of trypanosome killing as 
follows:  APOL1 associates with endosomal membrane at acidic pH, the membrane containing the 
pore recycles to the plasma membrane and opens the cation selective pore at neutral pH this leads to 
cytoplasmic swelling and lysis due to osmotic imbalance [75]. 
• APOL1 gene is under positive selection 
Apolipoprotein L1 is a protein component of the TLF complex that is expressed from the APOL1 gene, 
which is part of the APOL gene family. The APOL gene family consists of two clusters APOL1-APOL4 
and APOL5-APOL6. Of the two clusters, cluster 1-4 is of interest to us, which arose due to gene 
duplication in primates before separation of Old World Monkeys (OWM) from the New World Monkeys 
(NWM) [71]. The APOL3 in the cluster is predicted to be the ancestor gene based on its occurrence 
and evolution in primate lineage [76]. Although the product of gene duplication, the APOL1-4 have 
evolved rapidly to genes with their own identity. Infact, this gene cluster has been shown to be under 
positive selection, and the genes in the cluster are highly polymorphic in their sequences within the 
primate lineage [71].  
Within the APOL1 gene alone, we see a high degree of sequence variability, pseudogenization and 
deletion events among different primates suggesting that APOL1 is under positive selection. For 
example, when we compare the APOL1 sequence among different primates, human and gorilla 
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APOL1 sequences are similar to each other but different to the APOL1 sequences of OWMs such as 
baboons and Sooty Mangabeys [44, 55, 71]. This difference in APOL1 sequences in primate lineages 
is reflected in their ability to lyse multiple parasite strains. 
Human and Gorilla APOL1/TLF can lyse animal infective species of Trypanosoma brucei subspecies 
while OWMs’ APOL1/TLF lyse wider range of African Trypanosomes (both human and animal infective 
forms) [55, 77-79]. The difference in the APOL1 sequence of OWMs including baboons to that of 
humans at the C-terminus is remarkable. Baboon APOL1, which gives 100% resistance against T. b. 
rhodesiense, has four unique lysine residues at its C-terminus (Fig 5) that makes it possible to evade 
binding to the SRA of the parasites. Using chimeric APOL1 (human and baboon), our lab has 
previously shown that two out of four lysines at position 387 and 388 on the C-terminal domain of 






Figure 5: Alignment of C-terminus of human variants and baboon APOL1. 
The four unique lysine residues in baboon aligned to the lysine caused by an indel in G2 is in red. 
Base pair substitution in G1 is highlighted in yellow.  
 
The APOL1 gene is absent in chimpanzees and bonobos, the closest relatives of humans; and 
pseudogenized in macaques, closest relatives of baboons [71, 81]. Therefore, sera from these 
primates are not trypanolytic. Thus the presence of APOL1 is necessary for trypanolytic activity and 
hence innate immunity against African trypanosomes. It is possible that African trypanosomes 
were/are the selective pressure leading to the evolution of APOL1 in primates. One exception to this 
rule is Gibbons, which are predicted to have full open reading frame of APOL1 (XM_003264694.2) 
implying that there is a possibility of expression of APOL1 in gibbons. There is no evidence of the 
expression of APOL1 gene in Gibbons. In addition in vitro studies have shown Gibbons’ sera to be 







trypanolytic activity, geographical occurrence of Gibbons in regions of Asia support the fact that 
Gibbon sera are non-trypanolytic. We do not know the selective pressure for the evolution of APOL1 in 
Gibbons, primates that are geographically distributed in Indonesia and nearby regions of Asia. A 
parasite to blame is T. evansi, which evolved from T. brucei and infects domestic and wild animals in 
regions Gibbons are prevalent. The specific date of the evolution of T. evansi from T. brucei and its 
spread into these regions however, has not been resolved yet. [82] 
Selective evolution of APOL1 is observed within species as well. Population based genotyping studies 
have identified as many as 16 different haplotypes of human APOL1 existing within human 
populations [44, 83]. This result is supported by the result from a large-scale exome sequencing 
(~60,000 individuals) performed by broad institute that has been deposited in the ExAC database. 
According to this database, human APOL1 has 450 Single Nucleotide Polymorphism (SNP) variants 
and 46 Copy Number Variants (CNVs). Interestingly, the ratio of observed to expected variants for 
both synonymous and non-synonymous SNPs is greater than 1 indicating that APOL1 is rapidly 
evolving in human populations [35]. More recently, genome wide association studies, long range 
haplotype test, and genomic differential testing found three APOL1 haplotypes namely: G1, G2, and 
G3 are positively selected in different parts of Africa [44, 83-85]. These haplotypes are defined as- G1- 
two point mutations at rs73885319 (S342G) and rs60910145 (I384M), G2- inframe deletion at 
rs71785313 (delN388/Y389) and G3- rs136175 (p.M228I) and rs136176 (p.K255R) (Fig 4 and Table 
1).  Of the three, G1 and G2 have been shown to protect against Human African Trypanosomiasis 
(HAT) due to T. b. rhodesiense at the expense of a higher risk of chronic kidney diseases [44, 84, 85]. 
Due to its six base pair (two amino acids) deletion,  the C-terminus of G2 aligns with the lysine at 387 
to that of OWMs’ APOL1 (Fig 5). Due to this change in alignment, the C- terminus of G2 does not bind 
to SRA of T. b. rhodesiense as shown by surface plasmon resonance (SPR). The C- terminus lysines 
of G1 on the other hand do not align with OWM lysines and was found to bind to SRA with an affinity 
only slightly less than G0 in SPR binding experiments using the APOL1 C-terminus as bait [44]. The 
mechanism of killing of T. b. rhodesiense by G1 is not known yet. Unlike the immunity due to human 
TLF against animal infective forms that completely kills the parasites, the immunity due to human 
haplotypes G1 and G2 does not completely protect against T. b. rhodesiense infecton in Tg-mice. 
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Instead, these haplotypes were found to increase the survival rate of the mice, G2 being better than 
G1. Therefore, these haplotypes may be selected due to African trypanosomiasis in Africa where the 
disease has been endemic for past 3 million years [86]. However, G1 is highly selected (70% 
prevalence) in West Africa and coexists with the G2 (3% prevalence) suggesting that they may have 
been selected against two different pathogens. Haplotype G3 exists with very low frequencies in 
African populations and is positively selected in one Cameroonian population in West Africa indicating 
that G3 is a newly evolved haplotype [14]. This haplotype is not associated with the risk of kidney 
disease and matches with the Neanderthal APOL1, which is positively selected in the modern 
European population and is named G4 (Fig 4 and Table 1). Haplotype G4 represents 22% of the 
modern European population suggesting that Europeans acquired it from ancient human Neanderthals 
during interbreeding and that it must have been retained due to some selective advantage. Despite 
the fact that it is not the most common haplotype, G4 is reference gene for APOL1 (hg19). This 
haplotype matches the African haplotype G3 in all but two SNPs, one of which is a synonymous 
mutation [44] suggesting that G3 may have evolved from G4 due to interbreeding. We do not know the 
pressure driving the selection of G3 in Africa and G4 out of Africa. Given that APOL1 is an innate 
immunity gene, selection of APOL1 in distinct human populations may be driven by pathogens other 














4. Leishmania  
a. Disease and its distribution 
Leishmania are intracellular kinetoplastid parasites that cause a range of diseases collectively called 
leishmaniasis. There are 21 different species of Leishmania that cause human diseases ranging from 
mild cutaneous lesions at the site of infection called cutaneous leishmaniasis: moderate, 
disseminating mucocutaneous leishmaniasis to severe often life threatening visceral leishmaniasis. 
I. Cutaneous Leishmaniasis 
L. tropica, L. major, L. aethiopica, and rarely L. infantum and L donovani in the Old World cause 
cutaneous leishmaniasis. In the New World, the disease is caused by parasites belonging to the L. 
mexicana complex such as L. mexicana, and L. amazonensis. This is the most common form of 
leishmaniasis that is characterized by a mild self-healing lesion at the site of infection. The lesion 
usually starts as a bump that eventually opens to form ulcer. The ulcers are usually subject to 
secondary infections by bacteria. The skin ulcers often are covers with scabs. The lesion is most 
usually in the exposed part of the body such as face, neck, arms, and legs. The lesion therefore causes 
disfigurement in facial areas, which makes it undesirable as it may contribute to mental worries. 
Moreover, the disease is characterized by presence of more than one lesion often ranging to as many 
as 200 that leads to serious disability [87, 88]. According to CDC, there are approximately 0.7 million to 
1.2 million cases of cutaneous leishmaniasis worldwide [87]. The majority of these cases are from 
Afghanistan, Algeria, Brazil, Colombia, the Islamic Republic of Iran, Pakistan, Peru, Saudi Arabia and 
the Syrian Arab Republic. Some parts of South-East Asia have cutaneous leishmaniasis that cluster 
with visceral leishmaniasis and is believed to be of anthroponotic origin. In recent years, the disease 
outbreak has usually occurred in war conflict regions that have a dense population for example refugee 
camps [88].  
II. Muco-cutaneous leishmaniasis 
Mucocutaneous leishmaniasis is caused by Viannia subgenus (especially L. [V.] braziliensis but also 
L. [V.] panamensis and sometimes L. [V.] guyanensis); it also can be caused by L. (Leishmania) 
amazonensis. The disease is the disseminating form of cutaneous leishmaniasis that spreads from the 
skin to nasal and mucosal membranes [87]. The disease is common in the Americas due to 
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metastasis of the cutaneous lesions that were not treated or were suboptimally treated. The disease 
manifestation often happens years or sometimes even a decade after the initial infection. Untreated 
cases can progress and even destroy the entire naso-pharyngeal membrane.  
III. Visceral leishmaniasis 
Visceral leishmaniasis is caused by L. donovani in South-East Asia and parts of Africa. In some 
European countries and the Americas it is cause by member of L. chagasi complex mostly L. 
infantum. As the name indicates visceral leishmania spreads from the site of infection to viscera and 
affects internal organs of the reticulo-endothelial system particularly liver, spleen and bone marrow 
and is usually fatal if left untreated. The disease onset can be acute or chronic depending on the 
immunocompetency of the infected person. The common symptoms of the disease are fever, weight-
loss, lymphadenopathy, liver and spleen enlargement. Occurrence of the disease in HIV patients as a 
co-infection presents a big problem. Currently the majority of the cases are reported from Brazil, 
Ethiopia, Sudan, South Sudan, and Somalia. South Asian countries like Nepal, India, and Bangladesh 
where the disease was highly prevalent are poised to declare the eradication of disease by 2020 [87, 
88]. Approximately 0.2 million to 0.4 million new cases of visceral leishmaniasis are reported with 
20,000-40,000 deaths every year.  
b. Parasite and the Life cycle 
Leishmania sp. completes their lifecycle in sand-fly (vectors) and mammalian hosts like humans and 
dogs who also serve as the reservoir of the disease (Fig 6). Based on the animal or human reservoirs 





Figure 6: Life Cycle of Leishmania sp. 
Humans and other vertebrate hosts are infected A. when an infected sandfly injects metacyclic 
promastigotes of the parasite intradermally during a blood meal. B. Neutrophils are then recruited at 
the site of infection and are the dominant cells that phagocytose the metacyclic promastigotes on the 
first day of infection. C. Eventually the parasites enter macrophages where they reside in the acidic 
parasitophorous vacuole and transition into round non-flagellated forms, the amastigotes. D, E. These 
amastigotes are the dividing forms that divide and proliferate to manifest different disease symptoms 
in the host. F. Sandflies then take these parasites from the skin of an infected individual G., which 
transform into promastigotes in sandfly midgut. Source: Adopted from www.niaid.nih.gov [89] 
 
The parasites exist in different forms in the sandfly and vertebrate hosts that are described below: 
I. Sandfly 
Phleotomine sandflies of genus Plebotomous in Old World and Lutzomyia in New World spread 
leishmaniasis in humans and other vertebrate hosts [90]. Previous experiments have demonstrated 
species specificity between the sandfly and the Leishmania species [91, 92]. Although, there are 
differences, the major steps of metamorphosis of the parasites from the amastigotes to metacyclics 























Figure 7: Stages of Leishmania sp. in sandflies 
Sandflies take amastigotes from an infected vertebrate host during a blood meal into the abdominal 
midgut where the parasites transform into flagellated procyclics within 18-24 hrs. In 3-4 days the 
procyclics change to long slender Nectomonads. The nectomonads migrate to thoracic midgut and 
further transform to metacyclics and haptomonads. Finally the parasites migrate to foregut and are 
injected as non-dividing metacyclics into the vertebrate host during a blood meal to establish a new 
infection. Source: Sacks D., 2001. [93] 
 
The amastigotes ingested after blood meal lodge into the alimentary canal of the sandfly where they 
transform into flagellated procyclic forms in 18-24 hours. The parasites have to overcome different 
barriers like the chitin containing peritrophic matrix, hydrolytic enzymes and other innate immunity 
factors in sandfly gut [94]. Overcoming all these barriers, the parasites multiply and transform into 
nectomonads. The promastigotes at this stage attach to the midgut epithelium for their survival. Any 
promastigotes that fail to attach to the midgut epithelium are defecated by the sandflies. Therefore, 
this attachment is an essential step for the parasite development and propagation. One of the 
mechanisms by which the promastigotes attach themselves to the sandfly midgut is via the surface 
glycoprotein lipophosphoglycan (LPG) in the restrictive strains of the sandfly. It is the most abundant 
surface glycoprotein on the surface of the promastigotes that is made up of four domains: (a) a 
phosphatidyl inositol lipid anchor, (b) a phosphosaccharide core, (c) a repeating phosphoglycan region 
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(PG repeat), and (d) a small oligosaccharide cap (Fig 8). Of these four domains, the repeating 
phosphorylated saccharide region and the oligosaccharide cap are variable while the other two 
domains are fairly conserved throughout the species. The repeating phosphorylated saccharide has 
(6Galβ1,4-Manα1-PO4) core with the sugar branches and varies with the species and developmental 
stages (Fig 8). This variation in the glycan core or the cap structure has been shown to be the factor 
governing the species-specific attachment of Leishmania sp. to sandflies [95]. However, 
overexpression of the LPG binding receptor is not sufficient to enhance the establishment of infection 
by the parasites suggesting the existence of an unknown factor for the survival of parasites in their 
selective vectors [96]. In permissive strains eg. L. longipalpalis and P. arabicus, the attachment of 
promastigotes to the midgut is LPG independent. In these strains, vector glycans along with LPG2 






































Figure 8: A. The structural representation of L. major proteoglycans- LPG, PPG and GIPLs.  
The PGs are made up of a phosphatidyl inositol lipid anchor, a phosphosaccharide (glycan) core, a 
repeating phosphoglycan region (PG repeat), and (d) a small oligosaccharide cap. (Source: Adopted 
from [99]). B. LPGs of different Leishmania sp. (Source : Adopted from [100, 101]) 
 
Eventually, the parasites transform into the thin slendar, highly motile, terminally differentiated forms 
called metacyclics. Metacyclics are 5-8 microm in size, the non-dividing infective stage that are 
injected by blood feeding female sandlflies into the vertebrate host during a blood meal. 
II. Vertebrate host: 
Parasites are transmitted to the vertebrate host during a bloodmeal by an infected sandfly where the 
fly regurgitates the metacyclics into dermis accompanied by egestion of promastigote secretory gel 
(PSG) and salivary fluid [102, 103]. The PSG and sandfly saliva helps in establishment of the infection 
L. donovani procyclic 
L. infantum procyclic 
L. major procyclic 




and exacerbate disease when injected along with parasites in needle inoculation in rodents [102-104]. 
Mouse experiments revealed that sandflies inject L. major in the range of 10-105, though the range is 
segregated in two different clusters; a low dose with a median of ~40 parasites and a high dose with a 
median of ~8000. Clearly the progression of disease was different with different infection dosage. The 
high dose infection (5000 parasites) progresses rapidly with large lesion as compared to the low dose 
infection (100) [105].  
In vertebrate hosts, the Leishmania live as intracellular parasites in the cells of reticuloendothelial 
system. This process begins with the recruitment of neutrophils at the site of the infection following the 
sandfly bite. The recruitment of neutrophils has been observed within the first hour of infection and 
peaks at 12 hours post infection. Therefore, in the first several hours of infection, metacyclics are 
predominantly observed in the neutrophils [106-108]. These observations have been made in rodent 
models of infection, which are also used to assess the function of neutrophils in human leishmaniasis. 
In mice, depletion of neutrophils (first 24-48 hours post infection) leads to a decrease in parasite 
burden. This observation forms the basis of the hypothesis that neutrophils are a safe harbor for 
Leishmania [107-109]. The parasites in the neutrophils have been shown to be alive [106] and 
approximately 30% of the parasites were found to be released from infected neutrophils isolated from 
mice within 4-5 hours in vitro [107]. Therefore, it is possible that neutrophils release live parasites after 
phagocytosis, which may then be taken up (phagocytosed) by bystander immune cells such as 
macrophages and dendritic cells. Experiments performed by injecting infected neutrophils into mice 
suggest that the freed parasites are mostly taken up by macrophages and neutrophils. However, 
dendritic cells showed markers for neutrophils as well as fluorescent parasites suggesting that 
dendritic cells phagocytize apoptotic neutrophils as well as live parasites [107]. By 48 hours of 
infection, most of the parasites are observed in inflammatory monocytes and by day 4 of infection, 
there are very few neutrophils at the site of infection [94, 108]. By day 9 parasites are predominantly in 
macrophages following an ear infection [108]. In macrophages, Leishmania live as intracellular non-
flagellated amastigotes.  
Amastigotes are oval, 2-5um in size, non-flagellated forms that reside in the acidic parasitophorous 
vacuoles (PV) of macrophages. Depending on the species of Leishmania, the PV may be small and 
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tight carrying single amastigotes eg. L. major and L. donovani or large and communal carrying multiple 
parasites in one PV eg. L. mexicana and L. amazonensis. These forms divide by binary fission within 
the PV of the macrophages leading to the death of host cells harboring the parasites. The parasites 
are then released to infect new immune cells and thus proliferate in our body locally or viscerally 
depending on the species [110]. In this form they can manifest the disease symptoms in the infected 
hosts.  
c. Cell entry and survival in intracellular environment 
Leishmania encounters a barrage of host antimicrobial responses that they have to evade to establish 
a successful infection. These survival strategies range from being unrecognized by the host immune 
system to manipulating host cellular machinery for their survival and proliferation. Even before they 
reside in the cell they have to overcome complement mediated lysis, which they do by the activity of 
Leishmania surface protein GP63. It converts the active component of complement C3b into C3bi and 
thus evades the complement-mediated lysis by the Membrane Attack Complex (MAC). This process 
also facilitates the phagocytosis of the parasites by complement receptor 3 (CR3) mediated entry [111, 
112]. In addition, GP63 has been shown to inhibit the activity of natural killer (NK) cells by suppressing 
the proliferation and secretion of effector cytokines like IFN- γ. Recombinant biotinylated GP63 was 
found to interact with the NK cells to induce the same phenotype inferring that GP63 interacts with NK 
cells to inhibit its proliferation and cytolysis [113].  
Eventually immune cells like neutrophils and macrophages phagocytose the parasites. LPG the major 
surface glycoprotein plays an important role in the process of disease establishment by Leishmania. 
For example, LPG has been found to protect the parasites from killing by the neutrophils extracellular 
traps (NETs) [114].  
The phagocytosis and the host pathogen interaction that follows have been more extensively studied 
in macrophages than any other immune cells. The phagocytosis process initiates with the recognition 
of parasites and attachment, which occurs by using a range of macrophage receptors as CR3, 
mannose receptors, fibronectin receptors and Fcγ receptors [115]. Following this initial recognition by 
host cells, metacyclics are internalized into cells. The internalization of parasite can also occur by lipid 
raft mediated uptake that utilizes caveolae or cytoskeleton mediated uptake that utilizes actin [116]. 
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Once phagocytosed, metacyclics evade the phagosomal lysis by delaying the maturation of the 
parasitophorous vacuole. The surface glycoprotein LPG has been shown to inhibit the interaction of 
the parasite containing phagosome with late endosomes and lysososmes thereby delaying the 
biogenesis of the acidic PV [117]. This inhibition of PV biogenesis is related to parasite survival, as it 
has been associated with the reduction in the production of Reactive oxygen species (ROS) by 
macrophages [117].  
The metacyclics eventually transform into the non-flagellated amastigotes within macrophage, which is 
triggered by the decrease in pH and increase in temperature. These forms are highly adapted to 
survive in acidic PV and differ from metacyclics in several features. The surface glycoproteins such as 
LPG, PPG and GP63 are highly downregulated in the amastigotes. These parasites have reduced 
glucose and amino acid uptake and metabolism and increased beta-oxidation of fatty acids for the 
survival in nutrient deficient PV. In this form the optimal metabolic environment for the parasite is at pH 
4.0-5.5 [118]. Thus amastigotes are well suited for the growth in acidic PV. 
d. Immunity  
Multiple host, environmental and parasite factors govern the immune response to Leishmania sp. in 
vertebrate hosts. As an intracellular pathogen residing in cells of the reticuloendothelial system, 
immunity against Leishmania is remarkably complicated. From the studies done so far, immunity 
against both cutaneous and visceral strains of the parasite are driven primarily by cellular immunity. In 
humans, this immune response varies from strong T cell responses and delayed type hypersensitivity 
as observed in tuberculosis, to the absence of such a response. In other instances, there appears to 
be exaggerated immune responses giving rise to chronic progressive mucocutaneous leishmaniasis. 
The immune response in leishmaniasis can be divided into innate and adaptive immunity. 
I. Innate Immunity 
Once in the body of its vertebrate host, Leishmania sp. encounters variety of innate immunity factors. 
Neutrophils are the first cell to be recruited at infection site and hence to phagocytize parasite.[106]. 
Neutrophils can kill pathogens by phagocytosis, formation of extracellular traps, or by killing by 
activated neutrophils. Human and mouse experiments have demonstrated the existence of live 
Leishmania in the neutrophils of parasites [119, 120]. In fact, based on results from depletion studies 
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in rodents, neutrophils are considered safe harbor for Leishmania where they reside and hide until 
they are ready to invade macrophages [108, 109]. In these depletion studies performed by using anti-
Ly6G antibodies RB6C-8C5 and 1A8, the depleted mice are prone to T-cell activation indicated by 
increase in IFN-Υ and Leishmania specific ovalbumin [107]. Therefore, it is hypothesized that 
parasites hide in neutrophils and make silent entry into other cells to establish the infection. The role of 
NETs in leishmaniasis is unclear because of different results with different species. The NETs have 
been shown to kill promastigotes of L. amazonensis [121]. Some other studies have shown 
promastigotes of L. donovani and L. mexicana are resistant [119, 122]. 
Based on rodent experiments, apoptotic neutrophils with parasites are then taken up by dendritic cells. 
The dendritic cells in the presence of neutrophils are less prone to activation as seen by lower 
expression of MHC class II, CD86 and CD40 which are markers of dendritic cell activation [107]. 
Evidence suggest that a large number of parasites are also released alive into the extracellular milieu 
which are then taken up by immune cells like monocytes and macrophages [107, 108]. In 
macrophages, the parasites can grow silently. Alternatively, the macrophages can get activated 
mediated by IFNγ to induce Th1 response or by IL-4 to induce Th2 response thereby destroying the 
parasite [123]. The interferon gamma (IFNγ) plays an important role in the control of Leishmania in the 
macrophages by inducing the production of NO (nitric oxide), iNOS (inducible nitric oxide synthase) 
and ROS (Reactive Oxygen species) leading to the respiratory burst and the death of parasites [124].  
Natural Killer (NK) cells are immune cells that play an important role in the innate as well as adaptive 
immunity against Leishmania sp. The role of NK cells and their ability to produce cytokines such as 
IFNγ and tumor necrosis factor- alpha (TNF α), which are known to drive TH1 response associated 
with protection against leishmaniasis has been well studied [124]. In addition to cytokines, the 
activated NK cells also release cytotoxic granules such as perforin, granzymes and antimicrobial 
granulolysin. Recently, these cytolytic components have been shown to be antimicrobial against 
intracellular parasites such as Leishmania, Trypanosoma cruzi and Toxoplasma gondii [125]. 
II. Adaptive immunity 
Dendritic cells are one of the important cells that produce different cytokines and polarize T cells into 
TH1, TH2, TH17 or TReg phenotype, which determines the pathogenesis of leishmaniasis. Based on 
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early experiments done using susceptible BALB/c and resistant C57BL/6 mice, IFNγ and interleukin 
IL-12 driven TH1 immunity was associated with protection while IL-4 driven TH2 with exacerbation of 
leishmaniasis [124]. In human cutaneous infections, disease progression is associated with decreased 
level of IL-10 receptor suggesting that IL-10 plays an important role in the immunity against 
leishmaniasis [126]. IL-10 is an autocrine inhibitor of IFNγ production and is therefore associated with 
parasite persistence in organs like spleen in visceral leishmaniasis [127]. In addition, other factors 
such as prostaglandin E2 and TGFβ have been shown to have a role in immunity against 
leishmaniasis.  
III. TLF mediated immunity in leishmaniasis 
TLF is an innate immunity factor against leishmaniasis. Our lab has shown that TLF ameliorates 
cutaneous infection by intracellular Leishmania sp. in macrophages and in mice [28, 128]. This TLF 
mediated immunity is due to the ability of TLF to damage the infective metacyclics. The dividing 
amastigotes are resistant to TLF activity. Therefore, TLF activity against Leishmania is limited to the 
initial infective stage of the parasites. This may explain the persistence of some parasites even in the 
presence of TLF in both mice and macrophage infections. Thus TLF is an innate immunity factor that 
acts early in the Leishmania infection before the metacyclics transition into amastigotes. Although we 
have seen decrease in parasite burden in mice expressing TLF, we do not know the role of neutrophils 
in this transgenic murine model. We will revisit this model because recently neutrophils have been 
shown to be the first cells recruited to the site of the infection that uptake the metacylics.  
With respect to the role of macrophages, the parasites were found to co-localise with labeled TLF in 
the acidic PV. Therefore, it was hypothesized that TLF kills metacylics in the acidic PV [28, 128]. We 
do not know the mechanism for the uptake of TLF into macrophages. However, macrophages have 
scavenger receptors for uptake of HDL, which may be responsible for endocytic uptake of TLF., The 
receptor for HPHB, CD163 is not involved in TLF uptake in macrophages, because HPRHB is not 
recognized by the receptor. Nonetheless HPR is required for the amelioration of leishmaniasis in 
addition to APOL1, although HPR alone has no effect. Moreover, haptoglobin inhibits the toxic effect 
of TLF against Leishmania sp, but does not appear to compete for uptake into macrophages. We do 
not know the role of HPR or the precise mechanism of activity of TLF against Leishmania. In vitro co-
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incubation of purified TLF1 with purified metacyclic parasites shows swollen parasites from two 
cutaneous strains of Leishmania with a marked decrease in infectivity after 24 hours in acidic media 
suggesting that TLF may act by pore formation and eventual parasite lysis in Leishmania sp. as well 
[28, 128]. This provides evidence for the slow lysis of parasites within intracellular phagosome at 
slightly acidic pH.  In the case of African Trypanosomes, TLF can rapidly lyse the parasites within hour 
of co-incubation [53]. We do not know if there is a rapid lysis of Leishmania sp. by TLF similar to that 
observed in African Trypanosomes.   
TLF mediated protection has been observed for cutaneous strains such as L. major and L. 
amazonensis that cause self-healing cutaneous lesions [28]. Given that TLF reduces the parasite 
burden, we infer that human TLF naturally acts as a restriction factor for cutaneous leishmaniasis. This 
restriction of Leishmania is limited by the transformation of the parasites to resistant amastigotes, 
which are the proliferative forms that lead to disease manifestation. It is undetermined whether TLF 
provides any protective effect against visceral strains such as L. infantum and L. donovani, which have 
worse disease outcome than cutaneous leishmaniasis [28]. 
In this study, we further examined TLF mediated protection against Leishmania sp. First we tried to 
look at the effect of primate and different human haplotypes of APOL1 that make TLF to understand if 
there is a role of Leishmania in the evolution of APOL1 gene. Next we studied the effect of TLF on the 
parasites with respect to its activity in innate immune cells such as neutrophils and the possible 





MATERIALS AND METHODS 
Synthesis of plasmids with APOL1 haplotypes 
Plasmid DNA with APOL1 haplotypes was synthesized by Quick-change site directed mutagenesis-
using primers with the mutation and PfuUltra HF DNA polymerase (Agilent Genomics) following the 
manufacturer’s protocol. The PCR cycle was 950C- 30 s, (950C-30s, 550C-1min, 680C-1min/kb 
plasmid) x18 cycles. The original template DNA was digested using DpnI enzyme for an hour and the 
mutant plasmid was transformed into DH5α cells. 
Search for primate APOL1 
Blood- We obtained fresh human blood that was immediately stored in PAXgene Blood RNA Tube 
(PreAnalytix). The blood samples were then used for RNA isolation using High Pure RNA Isolation kit 
(Roche).  
Fibroblast and B cells- Fibroblast and B cells were obtained from Corriell Cell Repository. RNA was 
obtained using High Pure RNA Isolation Kit. 
cDNA was synthesized using an RT PCR Kit (Promega).   
Primers 
Primers used for the amplification of APOL1 genomic locus and cDNA are:  Human- HuAfwd 
(GAACCTGGGATGGAGTTGGG), HuArev (GATGTGGCCCCTGTAAGCTT)  
Baboon- DBabFEx4 (AGTGGTGGCTACTGCTGAAC), DBabREx5 (CTCGGTTGGAAAGGGAGCTT), 
BabEx5F (GCAGCAAAACCATCCAGGTG)  
Gibbon- GibL1Ex5Fw (CCGGTGTTATCTCTGACATCCT), GibL1Ex5Rev 
(ATGATCTCAAGGGGTGTGGC) 
Orangutan- OREX4F (GCCGTCACTCCTAAGGCATC), OREX5R (GGATTGGCTGTGGCTCATCT), 
OrEx5F (GCACGATAAAGGACAGCAGC) 
Trypanosome Infection 
Mice were transfected with 25ug of plasmid DNA with APOL1 haplotypes by Hydrodynamic Gene 
Delivery (HGD) as previously described [26, 80]. Gene expression, which results in circulating protein 
was tested 2 days post HGD by western blot using rabbit anti-APOL1 polyclonal IgG (1:10,000; 
Protein Tech) and anti-rabbit TrueBlot-HRP (1:5,000; Rockland). Mice were infected with 5000 mouse 
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passaged T. b. brucei 427 or T. b. brucei 427- SRA intraperitoneally on Day 2 post HGD. The infected 
mice were monitored for parasitemia and euthanized when the parasitemia reached 1 x 109/ml.. 
Parasites and media 
L. major strain Friedlin V1 (MHOM/JL/80/Friedlin) L. amazonensis (IFLA/BR/67/PH8) or L. infantum 
(MHOM/ES/92/LLM-320) or L. donovani (LD1S) promastigotes were grown in medium M199 (Gibco) 
[129]. When the parasites are grown to stationary phase (day XX), the infective-stage metacyclic 
promastigotes were isolated by density gradient centrifugation on a Ficoll (Sigma) [130]. 
Tissue and blood preparation  
Mice infected with L. major were euthanized 15 days-post infection and ears were removed and 
placed in 70% ethanol for 5 minutes. Using tweezers, dorsal and ventral sheets of the ears were 
separated and digested in 160ug/ml using Liberase TL (Sigma-Aldrich) in DMEM (Cellgro) at 37oC for 
90 minutes. After 90 minutes, ears were homogenized and processed for determining the parasite 
load or for staining and phenotypic analysis of cells described in later section.  
For the analysis of cell population from blood, 40ul of blood was collected from the tail vein and 
processed for staining and cell analysis by FACS.  
Parasite load determination  
For parasite load by qPCR, ears were harvested, dissolved in trizol (ZYMO Research) and DNA was 
isolated using Qiagen DNeasy Blood and Tissue kit following manufacturer protocol.. Parasite DNA 
was quantified using previously described primers that amplify the kDNA: forward - 5’-
CCTATTTTACACCAACCCCCAGT-3’ [JW11]; reverse - 5’-GGGTAGGGGCGTTCTGCGAAA-3’ 
[JW12] [131]. The housekeeping gene used was mouse-specific beta catenin amplified using 
previously described primers: b-cat-F–CTTGGCTGAACCATCAC; b-cat-R- 
GGTCCTCATCGTTTAGCA [132]. PCR was performed using the ViiA™ 7 Real-Time PCR System in 
a 20ul reaction mix with 10ul SYBR Green master mix (Applied Biosystems), 1umol each of the 
forward and reverse primers and 10ng of the template. The PCR was run for 40 cycles at 950C for 10 





Purification of human and bovine HDL 
The HDL from normal human serum was purified by density gradient centrifugation as described 
elsewhere [55]. The serum density was adjusted to 1.25 g/ml using potassium bromide (KBr) and 
centrifuged at 49,000 rpm (NVTi 65; Beckman) for 16 hours at 10°C. The top lipoprotein fraction was 
collected followed by density adjustment to 1.3 g/ml with KBr. Then 4 ml of the adjusted lipoprotein 
was layered under 8 ml of 0.9% NaCl and centrifuged at 49,000 rpm for 4 hours at 10°C (NVTi 65 
rotor; Beckman). The HDL was then harvested and dialyzed in Tris-buffered saline (TBS; 50 mM Tris-
HCl, 150 mM NaCl (pH 7.5) at 4°C and concentrated by ultrafiltration (XM300 filter membrane; 
Amicon). The concentrated HDL was purified by size fractionation using superpose 6 (GE Healthcare) 
Fast Protein Liquid chromatography and the fractions that showed 50% or higher trypanolysis were 
collected and concentrated [55].  
For the bovine HDL separation, following first float after density gradient centrifugation; HDL was 
purified by size fractionation on a Superose 6 column (GE Healthcare) equilibrated with TBS. Only the 
fractions containing APOA1 were then pooled and concentrated. 
Macrophage preparation 
Bone marrow-derived macrophages were prepared from femurs of BALB/c mice (Taconic) as 
described previously [133]. Bone marrow progenitor stem cells were cultured in conditioned medium 
supplemented with L-Cell supernatant 30% (v/v) at 370C (5% CO2, 95% air humidity). Adherent 
macrophages were harvested and replated into 8-well Lab-Tek II (Nalge Nunc International, 
Naperville, IL) at 50,000 macrophages per well. The cells were then allowed to adhere to the slides by 
incubating at 370C (5% CO2, 95% air humidity) for 24 hours in medium without L-Cell supernatant. 
Macrophage infection 
The infective metacyclic promastigotes of L. major, L amazonensis, L. donovani or L. infantum were 
opsonized by 30 minutes incubation in DMEM medium containing 4% A/J mouse (Jackson 
Laboratories) serum, which has a defect in C5 of the complement cascade. The parasites are thus 
coated in C3b but are not killed by the membrane attack complex. The C3b is recognized by CR1 
receptors on the macrophage, which facilitates phagocytosis. The multiplicity of infection (MOI) was 3 
or 2 parasites per macrophage performed in DMEM (Cellgro) medium for 2 hours at 33°C (L. major 
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and L. amazonensis) and 370C (L. infantum and L. donovani) (5% CO2, 95% air humidity) in the 
presence of human HDL, bovine HDL or no HDL. The parasites that were not phagocytosed were 
washed off and the cultures were incubated for different time periods in respective media (HDL or no 
HDL). Intracellular parasites were assessed after staining with DAPI (3 µmol/L) and visualizing under 
fluorescence microscopy. 
Leishmania acid lysis and acid priming in vitro 
For acidic lysis to mimick the endosome pH to lysosome pH change in macrophages, parasites were 
incubated in slightly acidic pH (5.6) in presence of human HDL (1 Lytic Unit) or bovine HDL (equivalent 
protein concentration) for an hour followed by further acidification to pH 4.5 by adding succinate buffer 
at pH 3.8. Live parasites were counted using a hemocytometer using 400X magnification and phase-
contrast.  
For acid priming to mimick the intial acidic endosome encountered in neutrophils followed by parasite 
release into the neutral extracellular space, L. amazonensis or L. infantum were acidified to pH 5.6 
using succinate buffer (pH 3.8) and incubated at 330C or 370C (5% CO2, 95% air humidity) for 1 hour 
in the presence of human or bovine HDL (1.5mg/ml). After 1-hour incubation in acidic pH (5.6), the 
media was neutralized to pH 7 using HEPES buffer (pH 8) and incubated for 2 more hours. Parasites 
were then washed to remove the HDL and buffer, opsonized in DMEM medium containing 4% A/J 
mouse serum and allowed to infect macrophages for two hours?. Parasites incubated in neutral 
medium with human or bovine HDL for 3 hours were used as control. 
Transfection and Leishmania infection of mice  
Transient transgenic mice were created by injecting plasmid DNA (APOL1:HPR) by hydrodynamic 
gene delivery as described previously [26, 80, 134]. One day post-HGD, plasma was collected by tail 
bleeding to analyze the expression level of both genes by western blot using a rabbit polyclonal anti-
APOLI antibody (ProteinTech 16139-1-AP - 1:10,000) or a rabbit polyclonal anti-HP antibody (Sigma 
H8636 - 1:10,000) as the primary antibody and TrueBlot anti-rabbit secondary antibody (Rockland 
Antibodies 18-8816-33 - 1:5000). On the same day mice were infected with 10,000 Ficoll (Sigma) 




HDL labeling and binding to parasites 
Human HDL was labeled with DyLightTM 488 NHS ester (ThermoFisher) according to the 
manufacturer’s instructions. Ficoll purified metacyclic promastigotes of L. major, mutants lpg5A-/lpg5B 
or add-backs lpg5A-/lpg5B-/ +LPG5A+LPG5B, L. amazonensis or axenic amastigotes were incubated 
(1 x 106/ml) with 10 µg/ml Alexa Fluor-488 labeled HDL in DMEM, 1% BSA for 30 minutes on ice. 
Cells were washed twice in DMEM with 1% BSA before being analyzed by flow cytometry. Cells not 
treated with labeled HDL were used as the controls. Flow cytometry was performed with a Becton 




PART I- LEISHMANIA AND THE EVOLUTION OF APOL1 
RESULTS 
1. The search for primate APOL1 
Previously we have shown that human TLF with most common haplotype of APOL1 (G0) ameliorates 
infection by cutaneous Leishmania sp.  Based on the long haplotype analysis, done in the samples of 
Thousand-genome database phase I, this haplotype is present in 80% of the population sampled [44] 
Table 1. Different population based studies have discovered APOL1 haplotypes that are present in 
people of African descent three of which are positively selected in specific populations in Africa. They 
are named G1, G2 and G3, where G1 and G3 are selected in West Africa while G2 is distributed 
throughout Africa (Fig 9, Table 1) [44, 84]. The haplotype G1 and G2 have mutations in their C-
terminal domain, the domain that binds to parasite resistance factor SRA. In fact, these haplotypes 
can kill the human infective T. b. rhodesiense in vitro and in mice. Considering their distribution and 
the ability to kill African Trypanosomes, it is possible that these haplotypes are selected due to 
pressure from African trypanosomes. One haplotype, G4, was found to be present only in population 
outside of Africa (Fig 9, Table 1). This haplotype matches the SNP of ancient humans Neanderthals 
and Denisovans in all but two (non coding) SNPs in a region of 8 KB [44] suggesting that modern 
humans got this haplotypes from ancient humans due to interbreeding and kept it due to some 
selective advantage in populations outside of Africa. Given that there is no African trypanosome 
pressure in these populations for past 3 million years, African trypanosomes cannot be the selection 
pressure for G4. Therefore, we hypothesize that another pathogen has driven selection of G4 in out of 
Africa population including ancient Neanderthals and Denisovans. The distribution of Leishmania sp. 
overlaps with the distribution G4 (Fig 9) G4 as well as of primates such as gibbons and orangutans 
(Fig 9). Here we wanted to test the effect of primate and human APOL1 on Leishmania sp. using 




Figure 9: Distribution of Leishmania and human APOL1 haplotypes 
Leishmania sp. are worldwide in distribution. . G1, G2 and G3 are African haplotypes selected in 
different parts of Africa while G4 originated out of Africa possibly in Europe and is still prevalent in 22% 
Europeans and 20% Asians. Adopted from Thomson et al 2014 [44] and WHO Leishmania map. 
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G3 G E N M R D S I NNY <0.05 <0.05 0 
G4 G E N M R D S I NNY 15.8 0.77 15.03 
 
 
It is very difficult to obtain sufficient non-human primate blood for TLF isolation, as most great apes 
and old world monkeys are protected species. Therefore, to test the effect of different non-human 
primate APOL1, we tried to obtain APOL1 cDNA from primate samples such as blood and fibroblasts 
and B-cells. The aim of doing so was to clone the cDNA into plasmid, which can then be expressed in 
mice to test their effect on Leishmania in vivo in our transient transgenic mouse model. 
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a. Search for APOL1 in primate samples 
Originally when discovered, APOL1 was found to be expressed in tissues such as liver, lung, 
pancreas, prostrate, brain, kidney, and some intestinal tissues[135]. With the advancement in 
technology, it was reported to be expressed in more cells and tissues indicating it’s ubiquitous 
expression based on microarray and RNA seq analysis [136]. Therefore, first we tested for the 
expression of the genes in primates that we knew had circulating TLF (APOL1 and HPR) in their 
blood. We screened human blood cells and baboon fibroblasts, representative of the cells that we 

















































Figure 10: Baboon fibroblast and human whole blood does not express APOL1  
A. Baboon APOL1 gene was amplified from genomic DNA of the samples as indicated using primers 
that amplifies a segment of exon 5 (longest exon). Amplification of baboon cDNA was done using the 
primers (exon4-exon5) flanking the intron. B. Human APOL1 was amplified from genomic DNA, cDNA, 
and no RT control using primer (exon 5). C. Orangutan genomic DNA and c-DNA from B cells were 
























To test the expression of APOL1 in baboon fibroblast, we obtained genomic DNA as well as cDNA 
from the fibroblast cells. Liver that has been previously shown to express APOL1 was used as positive 
control. We found that genomic DNA is present in baboon fibroblast as seen by the PCR amplified 
band of expected size. However, cDNA prepared from fibroblast cells did not have APOL1 band of the 
expected size (Fig 10 A) despite the fact that liver had the band of right size. This suggests that 
baboon fibroblast does not express APOL1. Based on this data, we conclude that fibroblast do not 
express APOL1.  
We also tested human whole blood for the expression of APOL1. We used genomic DNA extracted 
from blood or cDNA synthesized from mRNA using primer pairs HuAfwd (exon4), HuArev (exon5) 
flanking intron. We obtained expected band in our genomic DNA prepared from human whole blood 
(Fig 10 B). However, we did not observe APOL1 band in our cDNA suggesting that whole blood cells 
do not express APOL1. We did not observe expression of APOL1 in any of these cells tested, 
although presence of the gene within genomic DNA was confirmed.  
We also tested the presence of gene in orangutan B cells and gibbon fibroblast. Despite the presence 
of APOL1 gene in genomic DNA, We did not detect the expression of APOL1 in orangutan B cells. We 
do not know if orangutans express APOL1. There is a non-sense mutation at C862T in orangutan that 
leasds to early termination of APOL1 during translation. Therefore, it is possible that orangutan does 
not express the APOL1 gene. However, it is also possible that the gene is not expressed in B cells. 
Based on the result from baboon sample, fibroblast does not express APOL1. Therefore, we did not 
look for the expression of APOL1 in gibbon fibroblast cDNA. Based on these results we conclude that 
whole blood and fibroblast does not express APOL1. It is possible that B cells do not express APOL1 
as well. More experiments needs to be done to rule this out. 
 
b. Effect of Primate APOL1 in natural dermal infection 
Recently, our lab identified, sequenced and cloned baboon APOL1 cDNA from a liver sample, after 
necropsy. Although we could not obtain the APOL1 cDNA of other non-human primates, we have 
human APOL1 sequences (in silico) representative of hominoids and baboon APOL1 sequences 
(cloned from liver cDNA) representative of OWMs. Therefore, we tested the effect of human and 
baboon TLF against L. major. 
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I. Human TLF (G0) protects against L. major in natural dermal infection 
Previously, human APOL1 (G0) was shown to ameliorate infection by L. major in a subcutaneous 
footpad infection infected with 1x106 or 5X105 metacyclic promastigotes [28]. However, in the natural 
sandfly bite, fewer parasites are injected intradermally in the skin [137, 138]. Therefore, we tested the 
effect of TLF on L. major in an intradermal ear infection murine model at two different doses: 104 and 
106 metacyclic promastigotes per ear. We observed reduced parasite burden in the TLF expressing 
mice as compared to control mice in low parasite dose (104) but not in high parasite dose (106) (Fig 
11). Sandflies inject 10-105 Leishmania intradermally into the skin; therefore we conclude that TLF 
ameliorates infection only when infected at low doses. We further extrapolate this result in human 
infections where higher number of parasites inoculum is possibly required for lesion formation. 
              A. Low Dose (104 per ear)                  B. High Dose (106 per ear) 
Figure 11: TLF reduces parasite burden in low but not high dose L. major infection in murine 
ears 
Mice were transfected with plasmids containing APOL1 (G0) and HPR by hydrodynamic gene delivery 
(HGD). Expression of genes was confirmed by immunoblotting the mouse serum for proteins of 
interest using rabbit polyclonal anti-APOL1 antibody (Protein-tech) or rabbit polyclonal anti-Hp 
antibody (Sigma) (data not shown). Transfected mice expressing TLF with APOL1 G0 haplotype were 
infected in the ear with 104 or 106 ficol-purified metacyclics. Ears were harvested 15 days post 
infection and parasite burden was determined by limiting dilution assay. The data represents Mean ± 
SD of one typical experiment. Low dose infection has been repeated twice and the high dose infection 
was performed once. **p<0.001, ns-non significant, compared to saline (HGD) group, Student’s t test. 




















































II. Baboon TLF protects against cutaneous L. major. 
Human APOL1 ameliorates infection by cutaneous strains L. major and L. amazonensis in the 
macrophage and in murine models of infection. Therefore, we hypothesize that APOL1 from non-
human primates would also protect against cutaneous Leishmaniasis. To test our hypothesis, we first 
did macrophage infection with L. major in the presence of human/baboon HDL (TLF) and bovine 
HDL/no HDL (control). We found fewer parasites in macrophages in 24 hours when incubated with 
human or baboon HDL as compared to the control groups (Fig 12) suggesting that baboon TLF kills L. 
major within macrophages. To confirm this in vitro result, we infected our C57Bl/6 germline transgenic 
mice-expressing baboon APOL1 or the germline transgenic mice transfected with baboon HPR (by 
HGD) with L. major. Wild-type C57B6 mice were used as negative control. Likewise mice transfected 
with human APOL1: HPR dual plasmid that were previously shown to protect against L. major infection 
were used as positive control. As expected, the mice expressing baboon TLF i.e. both APOL1 and 
HPR had significantly reduced parasite burden as compared to control mice suggesting that baboon 
TLF ameliorates infection by cutaneous L. major. Mice expressing baboon APOL1 alone had no 
reduction in parasite burden at the site of infection indicating that APOL1 alone is not sufficient to 
protect against L. major infection (Fig 12). Although we do not know the reason for this, we have 
observed significantly smaller footpad lesion in mice expressing human APOL1 and HPR as compared 
to the control mice or the mice expressing either APOL1 or HPR alone. In addition, we have observed 
that haptoglobin inhibits TLF mediated killing of parasites in macrophages. Therefore, we conclude 
that HPR has vital role in TLF mediated protection against Leishmania sp. Likely by enhancing the 



















B. In vivo mice infection  
 
Figure 12: Baboon TLF ameliorates L. major infection in vivo 
Ficoll purified metacyclic promastigotes were used to infect A. 50,000 BMDM (MOI 3:1) in the 
presence of human, bovine or baboon HDL for 2 hrs. The macrophages were then incubated for 24 
hours in the presence of the respective HDLs after washing away the non-infecting parasites. 
Parasites inside macrophages were counted after staining with DAPI under fluorescent microscope. 
The data represents Mean ± SD of one typical experiment repeated twice **p<0.001, ns-non 
significant, compared to saline (HGD) group, ANOVA test. B. Mice were infected with 10,000 parasites 
as indicated. The number of parasites per ear was estimated by real time PCR on day 15-post 
infection. The data represents Mean ± SD of one typical experiment repeated twice. **p<0.001 
compared to saline (HGD) group, Mann-Whitney U test, Bonferroni Correction. n= Baboon 























































































c. Effect of human APOL1 Haplotypes against Leishmania sp. 
Human APOL1 is highly polymorphic with more than 16 haplotypes existing in different populations. 
Some of these haplotypes show geographic specificity and marks of positive selection (Table 1). The 
out of Africa haplotype G4 overlaps with the distribution of Leishmania sp. (Fig 9 and Table 1) in the 
modern world. Here we tested the effect of five common haplotypes and named G0-G4 and tested the 
effect of these haplotypes against L. major to test if there is a molecular arms race between APOL1 
and Leishmania sp. 
III. Haplotypes G3 and G4 are lytic only to animal infective African Trypanosomes 
Previously, we have shown that African haplotypes G1 and G2 were effective at protecting against 
both animal infective T. b. brucei and human infective T. b. rhodesiense in our mouse model [44]. 
Here we characterized the effect of G3 and G4 against animal and human infective African 
Trypanosomes. Plasmid DNA with genes G3 and G4 were synthesized by Quick-change site directed 
mutagenesis of the plasmid carrying APOL1 G0 haplotypes. Next we tested the lytic ability of the 
newly synthesized proteins against animal infective T. b. brucei and human infective T. b. 
rhodesiense. 
To test the effect of G3 and G4, we challenged the transfected mice expressing APOL1 haplotypes 
with T. b. brucei or human infective T. b. rhodesiense. We found both G3 and G4 like G0 protect 
against animal infective T. b. brucei (Fig 13). As expected, G3 and G4 that have mutations upstream 

















A. T. b. brucei    B. T. b. rhodesiense 
 
Figure 13: Human haplotypes G3 and G4 protects against animal infective T. b. brucei 
Mice were transfected with plasmid DNA containing different haplotypes by HGD. Two days after HGD 
when the protein expression is at peak, 5000 A. T. b. brucei were injected into n= Saline (6), G0 (7), 
G3 (4), and G4 (6) mice. The infection progression was observed by checking parasitemia in the mice 
which were euthanized at 109 parasites/ml. The data represents survival curve of one typical 
experiment that has been repeated twice. ***p<0.0001 and **p<0.001 compared to saline (HGD) 
group, Log-rank Test. B. T. b. rhodesiense were injected into n= 5 mice per group. Mice were then 
observed for parasitemia and euthanized at 109 parasites/ml. The data represents survival curve of 
one typical experiment that has been repeated twice.  **p<0.001 and ns- non-significant compared to 
saline (HGD) group, Log-rank Test 
 
 
IV. Effect of human APOL1 haplotypes on L. major infection 
Next we tested the effect of TLF containing these major APOL1 haplotypes against L. major in HGD 
mice infected with ficoll purified metacyclics intradermally in their ears. Saline HGD mice were used as 
controls. Parasites were counted by harvesting ears 15 days post infection. Ears were then digested 
and parasites were counted by limiting dilution assay as described elsewhere [139, 140].  We found 
that mice expressing TLF with APOL1 haplotypes G0, G2, G3 and G4 had fewer parasites as 
compared to saline mice. The reduction in the parasite number is significant for all of these haplotypes 
when analyzed by Mann Whitney U test with out the correction for standard error due to multiple 
pairwise tests. However, upon applying the bonferroni correction, only G3 and G4 had significant 
reduction in parasite burden. Haplotype G1 had similar number of Leishmania as the saline mice. We 
do not know the reason for lack of efficacy of G1 in killing the Leishmania parasites. However, four 
other haplotypes were protective against infection by L. major (Fig 14). Haplotype G1 is lytic to human 
infective T. b. rhodesiense and is toxic to mammalian cells when expressed from the cells. It has been 
shown to be associated with chronic kidney diseases in humans [84]. Given its toxicity to other cells, it 







































was surprising that G1 was not lytic to L. major in our HGD mice. Therefore, we looked at the 
expression of APOL1 in mice expressing G0 or G1 at different times to see if there is difference in 
expression of the gene due to the toxicity of G1 to the cells that have been transfected with the G1 




Figure 14: Most APOL1 haplotypes ameliorate an intradermal L. major infection in the ear 
Mice were transfected with plasmids containing APOL1 haplotypes and HPR by hydrodynamic gene 
delivery (HGD). Expression of genes was confirmed by immunoblotting the mouse serum for proteins 
of interest using rabbit polyclonal anti-APOL1 antibody (Protein-tech) or rabbit polyclonal anti-Hp 
antibody (Sigma). Transfected mice expressing TLF with different APOL1 haplotypes were infected in 
the ear with 104 ficol-purified metacyclics. Ears were harvested 15 days post infection and parasite 
burden was determined by limiting dilution assay. The data represents Mean ± SD of one typical 
experiment that has been repeated twice. **p<0.001 compared to saline group, Mann-Whitney U test 










Figure 15: Comparision of expression level of G0 and G1 in HGD mice 
Blood was collected from mice tail by tail bleeding on different days. The serum was separated using 
heparinized serum separator. The serum was serially diluted starting at 1:40 dilution and detected by 
western blot, using anti-APOL1 antibody (Protein-tech). 
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Our results show that APOL1 is not expressed in blood cells, B cells and fibroblasts (Fig 10). This is in 
agreement with the data from Serial Analysis of Gene Expression (SAGE) and the original paper that 
reported the expression of APOL1 in only some specific cells and tissues [135, 136]. Our results thus 
dispute the results of mRNA expression of APOL1 in these tissues as reported based on microarray 
and RNA Seq [136]. Our original aim was to use the cell lines to evaluate the expression of APOL1 in 
various non-human primates, however because the cell lines from primates that we know have 
circulating APOL1 within their blood are negative for APOL1 expression this approach was stopped. 
We continued our analyses with baboon APOL1 and human variants of APOL1. 
Previously we have looked at the effect of TLF against L. major in subcutaneous infection [28], 
because this is the common method used in the field of Leishmania research. Like in subcutaneous 
infection, TLF ameliorates infection by L. major in a more natural intradermal infection (as delivered by 
a sandfly) in a dose dependent manner (Fig 11). We observed an effect of TLF on low but not high 
parasite dose. This could be possible due to limited availability of TLF to kill intracellular Leishmania 
as TLF acts against the parasites in dose dependent manner [28]. In fact, the difference in fate of 
infection due to difference in cellular infiltration and cytokine production in low vs high dose has been 
previously described [105, 141]. The interplay between parasite dose, TLF and other immune 
components however, is yet to be investigated. 
Our results show that baboon TLF, like human TLF ameliorates infection due to L. major (Fig 12). This 
was anticipated as baboon TLF has been found to be lytic to wider range African Trypanosomes 
indicating its broad-spectrum activity [44, 73, 80]. Baboon APOL1 alone did not reduce parasites 
number comparable to APOL1 and HPR together in mice suggesting an important role of HPR in this 
TLF mediated protection against Leishmania sp. This is in agreement with previous data, where 
APOA1, HPR and APOL1 needed to be expressed in mice to get maximum protection against African 
Trypanosomes [80].  This result suggests that the assembly of the whole TLF particle is necessary for 
the activity of TLF against Leishmania. Similar results were observed for human TLF as well where 
mice expressing both HPR and APOL1 had smaller Leishmania lesions as compared to the groups 
expressing either protein [28]. We do not know the function of HPR with relation to Leishmania 
 
! 48!
infection. The fact that haptoglobin can inhibit the effect of TLF in macrophage [28] implies that it may 
play role in receptor mediated uptake of TLF in immune cells such as macrophages. 
Our result shows that primate and human TLF are effective at reducing L. major in mice. Based on this 
result we extrapolate that TLF is an innate immune factor against the parasite. However, humans get 
infected with Leishmania even though we have TLF in our blood. Similarly in our mice experiment, we 
have observed that the parasites persist in TLF mice although there is some reduction in parasite 
burden. This suggests that parasites although are killed by TLF, are successful at evading the host 
immune system to establish the infection. We have observed that parasite infectivity dose can govern 
the disease outcome (Fig 11). Therefore, it is possible that high dose inoculation of parasite in humans 
lead to successful establishment of infection as compared to the low dose inoculation. Alternatively, 
the inoculum dose of parasite may govern the disease pathogenicity and the timing of lesion 
development.  
Finally, we found that most of the human APOL1 haplotypes were effective at ameliorating infection by 
L. major. We found that G1, which kills human infective African Trypanosomes, did not reduce the 
parasite burden in L. major infection in mice (Fig 14). This result is surprising given that G1 kills 
broader range of African Trypanosomes and has higher toxicity to mammalian cells [84]. However, we 
have observed approximately two fold decrease in expression of G1 as compared to G0 in the HGD 
mice which may be due to toxicity of G1 to the cells expressing it (Fig 15). We know the effect of TLF 
is dependent on its dose [28]. Hence, the lack of effect of G1 against L. major may be due to the lower 
level of proteins in the HGD mice. Based on the haplotype results, we cannot conclude if G4 was 










PART II- MECHANISM OF TLF MEDIATED KILLING OF LEISHMANIA SP. 
RESULTS 
Previously we have shown that TLF ameliorates infection in macrophages. Microscopic examination 
using Alexa labeled TLF show that TLF and Leishmania colocalize in the parasitophorous vacuole of 
macrophages. Co-incubation of parasites with TLF shows reduced infectivity of parasites in acidic pH 
(5.3) but not at neutral pH (7.4) confirming that this TLF mediated lysis occurs within phagosome 
where TLF encounters the parasite at acidic pH (the parasitophorous vacuole) [28]. However, we do 
not know the activity of TLF against parasites in neutrophils the first cells to phagocytose the 
metacyclic promastigotes in the body after a sandfly bite [106]. Considering that metacyclic 
promastigotes of Leishmania sp. are phagocytosed into neutrophil phagosomes, we hypothesize that 
TLFs lyse parasites in neutrophil phagosomes. However, mouse experiments using a neutrophil 
depletion strategy have shown that depletion of neutrophils in mice leads to a reduction in parasite 
burden at the site of infection [106, 108, 109]. Moreover, in vitro infection of murine neutrophils shows 
evidence of lodging of parasites into phagosomes of lysosomal and endoplasmic reticular (ER) origin. 
The parasites in phagosomes with ER markers evade neutrophil mediated lysis [120]. Hence, it is 
assumed that these compartments are not acidic, which forms the basis of the argument for 
neutrophils being a safe harbor for the parasites.  
The effect of TLF is limited by the conversion of parasites to amastigotes because amastigotes of L. 
amazonensis are resistant to TLF activity. We do not know the reason for this resistance of 
amastigotes to TLF activity. We know that amastigotes are TLF resistant and are able to divide and 
proliferate in this stage. It is likely that the difference in TLF activity against Leishmania life cycle 
stages is accountable for the difference in disease outcome. As such proliferating amastigote forms of 
L. infantum and L. donovani may be resistant to TLF. Although effect of neither TLF nor APOL1 has 
been tested, previous data suggests that APOL1 may protect against more virulent form of 
leishmaniasis by L. donovani and L. infantum. For example, linkage analysis has shown D22S280 at 
chromosome locus 22q12.3 is responsible for susceptibility to visceral leishmaniasis by L. donovani 
[142]. This locus is very close to the APOL1 gene locus. Likewise, increased HDL level confers 
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resistance to infection by L. infantum in humans [22]. Hence it is possible that like L. major, TLF kills 
the metacyclic promastigotes of visceral Leishmania strains.  
Here we attempted to answer some of these unanswered questions by testing the effect of neutrophil 
depletion on TLF activity and investigating possible mechanism of TLF activity against the parasites. 
We also tested the effect of TLF against the more virulent L. infantum.  
1.  TLF kills Leishmania sp. within neutrophils 
To test the effect of neutrophils on TLF activity, we adopted a neutrophil depletion strategy using the 
depleting antibody 1A8 in our transient TLF transgenic mice (transfected by HGD). First we checked 
the effect of HGD on blood neutrophils. We collected blood from our HGD or control mouse (no HGD) 
and stained the cells with anti-CD11b, anti-Ly6C and anti-Gr-1 (Ly6G) (1A8). Gating strategy for cells 
is shown in figure 16. We found that our HDG mice had a higher frequency of neutrophils in blood as 








































Figure 16: Gating strategy to identify neutrophils in mouse blood and ear  
A. Murine blood (50ul) was collected by tail bleeding, B. Murine ears were collected 12 hours after 
injection of (1x106 metacyclic promastigotes) and processed as described in methods. The blood/ear 
cells were stained with anti-mouse CD11b PE, anti-mouse GR-1 (antiLy6G) FITC, and anti Ly6-C APC 
and measured by Flow cytometry in BD FACSCalibur™.  Total cells were then sorted for CD11b+ 
cells. CD11b+ lineage cells were then divided into sub-populations. Neutrophils are identified as the 
CD11b+Ly6G+Ly6C+ subpopulation (when depletion was performed with 1A8 antibody) otherwise 
























Figure 17: HGD mice have high neutrophil recruitment in blood 
Mouse blood was collected from the tail vein two hours post HGD. Neutrophil frequency in mouse 
blood was measured by staining with fluorescent antibodies followed by flow cytometry as described 
above in Fig. 14 Frequency of neutrophils (CD11b+Ly6G+(Ab1A8)Ly6C+) increases due to A. HGD as 
compared to B. No HGD mouse control.  n= 1 mice per group.  
 
Next, we looked at the effect of neutrophils in TLF mediated immunity against Leishmania sp. We 
depleted neutrophils in mice by intraperitoneal injection of 1mg anti-mouse Ly6-G 1A8 antibody 6 
hours post HGD (24 hours before infection). Isotype IgG antibody was injected as control. Since we 
used 1A8 antibody for depleting the neutrophils, we used a different antibody RB6-8C5 (Ly6-G Ly6-C) 
for identifying the neutrophil population (Fig 16). This is done to make sure the depletion we observed 
is not due to masking by the 1A8 antibody. At 1mg antibody concentration of 1A8, although neutrophil 
depletion in blood is not complete (Fig. 18 A and C), we got good reduction in the number of 
neutrophils in ear (site of infection) (Fig. 18 B). Incomplete neutrophil depletion may be due to the 
increased neutrophil frequency in our HGD mice.  In addition, 1A8 antibody is not very efficient at 
depleting neutrophil especially in blood [108]. Despite these limitations, 1A8 is the most specific 
antibody available for the depletion of neutrophils at the moment [108, 143]. We used saline HGD 
mice injected with 1A8 or IgG isotype as controls. Neutrophil depletion at the time of ear infection was 
approximately 60% in blood (Fig. 18A). Twelve hours post infection (36 hours post initiation of 
neutrophil depletion) the neutrophil depletion was still 70% in the ear (Fig. 18B). As expected, there 
was a reduction in parasite burden (ear) in the saline HGD neutrophil depleted group when compared 
to the IgG isotype control (Fig. 18D). We see a reduced parasite burden in TLF expressing mice in the 
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presence of neutrophils suggesting that TLF act against L. major. However, the parasite burden 
increases when neutrophil is depleted from TLF expressing mice (Fig 18D). The number of parasites 
in our neutrophil depleted TLF mice was comparable to that of the neutrophil depleted saline mice 
suggesting that the increase in parasite number is not merely due to the effect of antibody. However, 
increase in the number of parasites in the neutrophil depleted TLF mice and the equivalent number in 
the neutrophil depleted saline mice suggests that some parasites evade TLF lysis as well as 
complement-mediated lysis in these mice and successfully establish infection. Since Leishmania are 
intracellular parasites, the most likely explanation for this result is that these parasites possibly infect 
some other cells in the absence of neutrophils. Previous results done in neutrophil depleted mice 
using 1A8 antibody suggest that most of the parasites do not infect other immune cells such as Ly6Chi 
monocytes, Ly6C low macrophages and dendritic cells in the absence of neutrophils [108]. Therefore, 
there may be other immune cells that are phagocytizing the parasites in the absence of neutrophils 
where they are not affected by TLF. We know TLF activity against Leishmania is dependent on the 
concentration of TLF [28, 128]. The abundance of TLF is approximately 10 times lower in interstitial 
tissue fluids as compared to plasma level[144]. Therefore, it is likely that L. major is taken up by tissue 
resident immune cells upon depletion of neutrophils by 1A8 antibody. This would explain the survival 
of the parasites in our TLF expressing mice in the absence of neutrophils. Nevertheless, our result 
shows that TLF kills L. major in immune cells such as neutrophils. Thus TLF and neutrophils synergize 
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Figure 18: Neutrophils and TLF synergize to ameliorate  
Neutrophils were depleted in mice using 1mg anti-mouse Ly6-G 1A8 antibody or an isotype control 6 
hours post-HGD. Neutrophil counts were assayed 24 hours post-depletion by collecting blood from the 
tail, staining for indicated surface markers and, analyzing by flow cytometry.  Representative dot plots 
and gating strategy for A. blood from mice injected with 1A8 or isotype antibody at the time of infection 
(+/-30 min) B. ears from mice injected with 1A8 or isotype antibody 12 hours post-infection with L. 
major.  C. The bar graph depicts total number of neutrophils (CD11b+Ly6G+Ly6C+) in blood after 
FACS in neutrophil depleted 1A8 antibody (grey bar) or isotype antibody controls (black bar) at the 
time of infection. ,**p< 0.001 student t test. D. Number of parasites quantified by real time PCR in 
mouse ears harvested 15 days post-infection. The data represents Mean ± standard deviation (SD) of 
one typical experiment that has been repeated twice. ns= non-significant and *p<0.05 Mann-











































2. TLF rapidly lyses metacyclic promastigotes when released from neutrophils 
Based on the results from macrophage and in vitro experiments [28], we hypothesize that the 
synergism between TLF and neutrophils happens in the neutrophil phagosome where TLF has the 
potential to directly interact with the parasites. Previously, we have shown that a 24-hour incubation of 
TLF with parasites in acidic media (pH 5.3) reduces the infectivity of the treated parasites for 
macrophages. The survivor parasites will transform into amastigotes and begin to divide by 72 hours. 
In contrast to macrophages, which live for 6-16 days neutrophils are short-lived cells that live for 5-90 
hours and do not support the growth of amastigotes [145]; furthermore infected neutrophils isolated 
from murine ears were found to release approximately 30% of the metacyclic promastigotes within 4-5 
hours [107]. Therefore, we hypothesized that there is an alternate pathway for the rapid killing of 
Leishmania in neutrophils.  
The fate of the metacyclic promastigotes invading neutrophils with respect to pH is to go from neutral 
pH (extracellular milieu) to slightly acidic pH in the phagosome to neutral pH in the extracellular pH 
(upon being released from the neutrophils). We mimicked this in in vitro where we co-incubated 
parasites with human HDL (which has TLF) or bovine HDL (negative control) in acidic media pH 5.6 to 
mimic the phagosome for an hour followed by neutralization (to pH7 to mimic extracellular milieu). The 
one-hour incubation in acidic media theoretically allows APOL1 to become membrane associated. We 
have observed that it takes approximately an hour for APOL1 to become membrane associated in a 
bilayer experiment using physiological salt concentrations. Also longer incubations in acidic media 
cause the parasite to begin a differentiation program into amastigotes. Parasites co-incubated with 
human HDL (TLF) or bovine HDL (no TLF) in neutral media for 3 hours were used as our control. 
Survivor parasites were evaluated after removing extracellular HDL (3 washes in PBS) by allowing 
them to infect 50,000 macrophages assuming that only live parasites are capable of infecting 
macrophages. Therefore, lower infection rates would be indicative of a diminished number of healthy 
parasites due to TLF-mediated damage during the acid primed assay (pH 5.6 followed by pH 7). We 
observe a significant reduction in the number of parasites per 100 macrophages in acid primed L. 
amazonensis co-incubated with Human HDL (TLF) but not with bovine HDL (no TLF) (Fig 19A). These 
data suggest that TLF induces damage in metacyclic promastigotes of Leishmania sp. that initiates in 
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the acidic phagosome. This damage is Human HDL specific, as we do not see such decrease in 
parasite infectivity in the presence of bovine HDL. However, macrophage infection assay did not 
address if the reduced infectivity is due to direct interaction of TLF with parasite leading to lysis as in 
the case of African Trypanosomes. Another caveat of the assay was long incubation in neutral pH (2 
hours neutralization plus an hour infection =3 hours). Therefore, the infectivity reflected the death of 
parasites in 4 hours. We were interested to test how early can we observe this TLF mediated damage 
to test if parasite would be damaged when released from neutrophils in an hour. To test if TLF directly 
lyse the parasites, and to determine the earliest time this lysis can happen, we counted the intact 
parasites using hemocytometer an hour after neutralization (Fig 19 B). As expected, we observed 
reduction in parasite number in presence of human HDL (TLF) but not bovine HDL in the acid primed 
condition but not in acidic media only (pH5.6) or neutral media only (pH7.4). This difference in parasite 
count is not statistically significant. However, we see a significant reduction in the parasite infectivity 
when acid primed in the presence of human HDL (TLF) as compared to the bovine HDL control (Fig 
19 A & B). It could be due to the fact that longer incubation is necessary after priming in acid to get a 
significant difference in parasite number. Alternatively, it could be that some of the parasites are 
damaged but yet not lysed, which may decrease the number of parasites in macrophages due to 
decreased phagocytosis or survival of the damaged Leishmania in the macrophages.  Based on these 
observations, we extrapolate that TLF rapidly lyses metacyclic promastigotes of L. amazonensis upon 
being released from neutrophil phagosome due to acid priming. Hence we conclude that neutrophils 
are essential for TLF mediated protection of Leishmania.  
3. TLF rapidly lyses metacyclic promastigotes in parasitophorous vacuole 
The fate of parasites in macrophages is different than in neutrophils as metacyclic promastigotes in 
the macrophage phagosome ultimately transform to amastigotes in the acidic parasitophorous vacuole 
during phagosomal maturation. Although we do not know the pH of phagosome harboring metacyclic 
promastigotes, the pH of macrophage parasitophorous vacuole harboring L. amazonensis 
amastigotes can be as low as 4.8 [146]. To study if TLF mediated rapid killing happens in the 
parasitophorous vacuole, we mimicked the parasites natural fate during the maturation of the 
parasitophorous vacuole by vATPase delivered by endosomes, which pumps H+ into the vacuole. We 
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subjected the metacyclic promastigotes to gradual acidification in the presence of human HDL. Human 
HDL or bovine HDL was added to parasites in neutral media (mimicking the extracellular environment) 
followed by acidification to an initial phagosomal pH 5.6 [147]. Parasites were incubated for 1 hour at 
pH 5.6 to allow the insertion of APOL1 into the parasite membrane followed by a second acidification 
to mimic parasitophorous vacuolar maturation (pH4.5) [146]. To assess the number of parasites alive, 
we could not perform a macrophage infection assay, because the macrophages did not survive the 
acidic pH incubation and if we neutralized the media prior to infecting the macrophages we would 
perform an acid prime experiment as above. Therefore, we used the microscopic count as the 
measure to assess the number of intact parasites after 1-hour incubation at pH 4.5 (Fig 19 B). We 
observed complete lysis of parasites after an hour of incubation at pH 4.5 in the presence of lytic 
human HDL (TLF), which is not observed in neutral pH or pH 5.6 incubation with Human or bovine 
HDL (Fig 19 A & B). This result implies that TLF lyse the parasites in acidic parasitophorous vacuole 
due to gradual decrease in pH during phagosomal maturation.  












Figure 19: Metacyclic promastigotes are lysed upon acid priming 
Ficoll purified metacyclic promastigotes of L. amazonensis were treated with human or bovine HDL 
and incubated at different conditions,  A. N- pH 7.4 for 3 hrs, AP- 1h at pH 5.6 an 2 hrs at pH 7. 
Parasites were washed and opsonized to infect 50,000 BMDM for 1 h. Parasites per macrophages 
counted by DAPI staining under fluorescent microscope. B. N-pH 7 for 2 hrs, A- pH 5.6 for  2 hrs, AA- 
pH 5.6 1 hr and 4.5 1 hr, AP- pH 5.6 1 hr followed by pH 7 1 hr. Parasites were microscopically 
counted using hemocytometer. The data represents Mean ± standard deviation (SD) of one typical 


















































3. Amastigotes are resistant to TLF mediated lysis  
Previously, we have shown that TLF does not reduce the infectivity of amastigote forms of the 
cutaneous strain L. amazonensis when incubated in acidic media (pH5.3) for 24 hours implying that 
amastigotes are resistant to slow lysis by TLF. Here we tested if amastigotes are resistant to rapid 
lysis by TLF. To test this, we incubated axenic amastigotes of L. amazonensis with human or bovine 
HDL at pH 5.6 for an hour (to mimick the phagosome) followed by neutralization (acid primed) or 
further acidification to pH 4.5 (gradual acidification, to mimick maturation to the phagolysosome). We 
did not observe any difference in parasite count/ lysis in the presence of human or bovine HDL in both 
acid priming and gradual acidification conditions confirming that amastigotes are resistant to TLF 
activity (Fig 20).  














Figure 20: Amastigotes are resistant to TLF activity 
Ficoll purified metacyclic promastigotes of L. amazonensis were treated with human or bovine HDL 
and incubated at different conditions as indicated. Parasites were microscopically counted using 
hemocytometer. Legends N-pH 7 for 2 hrs, A- pH 5.6 for 2 hrs, AA- pH 5.6 1 hr and 4.5 1 hr, AP- pH 
5.6 1 hr followed by pH 7 1 hr. Parasites were microscopically counted using hemocytometer. The 
data represents Mean ± standard deviation (SD) of one typical experiment that has been repeated two 
times. ns- not significant,  as compared to bovine HDL treatment under same conditions. ANOVA.  
 
4. Visceral strains L. infantum and L. donovani are resistant to TLF activity 
Our result shows that the non-dividing metacyclic promastigotes of two cutaneous strains of 
Leishmania, L. major and L. amazonensis are lysed by TLF. In contrast, the dividing amastigotes that 
establish disease are resistant to TLF activity. Therefore, we looked at the effect of TLF against the 
more virulent strains of Leishmania that can proliferate in the body beyond the site of infection to 
understand if susceptibility of parasites to TLF plays a role in the outcome of infection. Our hypothesis 
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was that more virulent strains like L. infantum and L. donovani are TLF resistant and hence can 
proliferate beyond the site of infection. To test effect of TLF on parasites in vitro, we infected primary 
bone marrow derived mouse macrophages with ficoll purified infective metacyclic promastigotes  (MOI 
3:1) of the respective parasites in the presence of human HDL (TLF), bovine HDL (no TLF) or no HDL 
(control). Parasites were counted using a fluorescent microscope after staining the slides with 
fluorescent nuclear stain. We did not see a significant difference in the number of parasites per 100 
macrophages counted when incubated with human HDL, bovine HDL or no HDL controls at different 
time points suggesting that visceral strains of Leishmania are resistant to TLF activity (Fig 21 A). The 
decrease in parasite burden observed at 48 hrs in L. infantum in bovine HDL (Fig 21 A) is not due to 
TLF, as bovine HDL does not have TLF.  
In the L. donovani macrophage assay we observed a constant decrease in parasites numbers in 
macrophages over time (Fig 21 B). Given that L. donovani is very virulent parasite, we suspected the 
death of macrophages due to parasite growth that may lead to fewer parasites being counted. To test 
if there is macrophage death due to parasites, we performed Lactate Dehydrogenase (LDH) assay. 
Lactate Dehydrogenase is a cytosolic enzyme present in macrophages but not parasites. Therefore, if 
there is cellular damage or death, this enzyme will be released on to the media. We tested the release 
of LDH in macrophages infected by both L. infantum and L. donovani. We observed a significantly 
higher LDH titer in L. donovani as compared to L. infantum within 24 hours (Fig 21 C). Thus we found 
that L. donovani has a complex tropism in which it successfully kills the host cells to possibly infect 
new one. This phenomenon possibly allows for the pathogen to successfully proliferate to visceral 
organs like spleen and liver to cause visceral leishmaniasis.  We speculated that this might complicate 
and make it to discern the role of TLF in parasite proliferation in L. donovani. Therefore, we decided to 






















Figure 21:  Visceral strains are resistant to TLF activity in macrophages 
Ficoll purified metacyclic promastigotes of A. L. infantum and B. L. donovani,were opsonized and used 
to infect 50,000 macrophages MOI (3:1) in the presence of human, bovine or no HDL. After 2 hrs 
infections, the unphagocytosed parasites were washed off and the infected macrophages incubated 
the in respective media with or without HDL for 24 or 48 hours changing media every 24 hours. C. The 
media of each experimental condition were collected at 24 hrs and the concentration of LDH was 
estimated. The data represents Mean ± standard deviation (SD) of one typical experiment that has 
been repeated three times, twice for LDH. *p<0.005, ***p<0.0001, ANOVA.  
 
To understand if this TLF mediated resistance is due to the ability of parasite to evade lysis by TLF, 
we performed the acid priming and gradual acidification experiments using L. infantum. The ficoll-
purified metacyclic promastigotes parasites were treated with human or bovine HDL in acidic media 
(pH 5.6) for one hour. The parasites were either neutralized (pH 7.4) or further acidified (pH 4.5) and 
incubated for 1 more hour. Parasites incubated in neutral media (pH7.4) for 2 hrs were used as a 
control. We did not see a significant difference in the number of parasites between lytic human HDL 






















































































































Figure 22: L. infantum is resistant to TLF activity in vitro 
Ficoll purified metacyclic promastigotes of L. infantum were incubated with human HDL (TLF) or 
bovine HDL as indicated. Parasites were microscopically counted using hemocytometer. The data 
represents Mean ± standard deviation (SD) of one typical experiment that has been repeated twice. 
ns-non significant, ANOVA.  
 
 
To determine the relevance of our macrophage infection and in vitro result, we tested the effect of TLF 
on the visceral strain L. infantum in vivo in our transiently transgenic mice created by HGD injection of 
plasmid DNA encoding the APOL1 and HPR genes. One day after HGD, when the gene expression 
peaks, they were infected intradermally in the ear with 106 ficoll purified L. infantum metacyclics. 
Disease burden was assessed by quantifying the number of parasites in the liver harvested 15 days 
post infection using qPCR as described elsewhere [132]. We saw no difference in the parasite burden 
in TLF or control mouse livers corroborating our in vitro result that L. infantum is resistant to TLF 
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Figure 23: TLF has no effect on L. infantum in vivo 
Mice were transfected with plasmid DNA containing APOL1 and HPR by HGD. A day post HGD, mice 
were infected with 106 metacyclic promastigotes per ear. Liver samples were harvested from mice 15 
days post infection. The data represents Mean ± standard deviation (SD) of one typical experiment 
repeated twice. ns-non significant, compared to saline (HGD) group, ANOVA test. n = saline (2), TLF 
(4) 
 
5. HDL binds to metacyclic promastigotes of L. infantum  
Previously we have found that HDL binds to the TLF susceptible metacyclic promastigotes but not to 
resistant amastigotes of cutaneous Leishmania [128]. Like the amastigotes of cutaneous Leishmania 
(Fig 20), we have found metacyclic promastigotes of visceral L. infantum to be resistant to TLF activity 
(Fig. 21, 22 & 23). Therefore, we tested the binding of HDL to the metacyclic promastigotes of visceral 
L. infantum. We incubated Alexa-488 labeled lytic HDL with the parasites and the fluorescent intensity 
of the parasites was measured to test if the HDL bound to the parasite. We used metacyclic 
promastigotes of L. major, to which HDL binds [128], as positive control. Metacyclic promastigotes of 
L. infantum or L. major not treated with labeled HDL were used as background fluorescence controls. 
We observed an increase in fluorescent intensity in the parasites co-incubated with labeled HDL as 
compared to the background control in both L. infantum and L. major (Fig. 24) suggesting that HDL 
binds to the metacyclics of these parasites. The fluorescence intensity of HDL coated L. major was 


































Figure 24: HDL binds to metacyclic promastigote of L. infantum 
Metacyclic promastigotes of L. infantum (red) or L. major (blue) were incubated with alexa-488 labelled 
lytic HDL for 30 minutes on ice. L. infantum (black) or L. major (green) not treated with labeled HDL 
were used as background control. Free labeled HDL that did not bind to parasites were washed and 
the fluorescence was determined by flow cytometry using BD FACSCalliburTM. 
 
The difference in fluorescence intensity between L. major and L. infantum metacylic promastigote may 
be due to the differences in the surface phosphoglycan structures between the two parasites, as the 
binding was conducted at 4oC. 
6. Glycosylation deficient mutants are resistant to TLF activity 
In our in vitro assays we have observed that TLF lysed parasites just by changing the pH of the media 
(i.e. ostensibly mimicking the pH of parasites extracellular environment) coupled with the FACS data 
suggests that TLF binds and lyses the parasites without being endocytosed by the parasite. In 
addition, amastigotes of L. major and metacyclic promastigotes of L. infantum are resistant to TLF 
activity.  One of the differences in the surface composition between TLF susceptible L. major 
metacyclics to TLF resistant L. infantum metacyclics or L. major amastigotes is the surface 
glycoproteins (Fig 25). The surface glycoproteins such as LPG and PPG are down regulated in all 
amastigotes when compared to metacyclics. Likewise, the surface glycoproteins of L. infantum are 
different to the surface glycoproteins of L. major metacyclics due to differences in glycosylation and 
the length of (6Galβ1,4-Manα1-PO4) core (Fig 25). Previously, we have tested effect of TLF on lpg1- 
mutants that lacks the LPG core galactofuranosyl transferase LPG1 and are specifically deficient in 














LPG synthesis (See Fig. 8 The structural representation of L. major proteoglycans-LPG, PPG and 
























Figure 25: Surface phosphoglycans in L. major metacyclic promastigotes and in mutants.   
A. The surface of lpg1- lakcs the surface PG, LPG (black box) that is other wise present in the WT 
metacyclics. The lpg5A-/lpg5B- lacks the golgi glycosylation enzymes LPG5A and LPG5B and 
therefore can not synthesize the PG repeats in the LPG and PPG (red box). Therefore, these strains 
have defective LPG and PPG. B. LPGs of different Leishmania sp. are different. 
 
 
L. donovani procyclic 
L. infantum procyclic 
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Next we tested the effect of TLF on lpg5A- /lpg5B-. These mutants are deficient in two genes lpg5A 
and lpg5B and therefore cannot uptake UDP-Gal into the Golgi. These mutants are defective in the 
synthesis of proteoglycans such as LPG and PPG [99]. We found the lpg5A- /lpg5B- mutants were 
resistant to TLF activity in vitro, in macrophage infections and in vivo in mice (Fig. 26 A, C & D).  
To confirm that deleting lpg5A and lpg5B genes results in TLF resistance, we performed macrophage 
infections, in vitro TLF killing assays, and in vivo ear infections with complemented lines lpg5A-/ lpg5B- 
/+LPG5A+LPG5B [99]. Like the mutants lpg5A-/ lpg5B-, the complemented parasites were also 
resistant to TLF activity in macrophage infections or in vitro lysis assays as seen by an equal number 
of parasites in the presence of human or bovine HDL. (Fig. 26 B). This result was supported by an in 
vivo infection assay, where equal numbers of parasites were observed at the site of infection (ear) in 
both TLF expressing mice and the controls (Fig 26 D). We do not understand the reason for the 
resistance of lpg5A-/ lpg5B- /+LPG5A+LPG5B to the TLF activity despite gaining the glycosylation 
genes at this time. We evaluated the efficiency of the complementation. Western blot analysis of the 
surface glycoproteins revealed lower expression of surface glycoprotein (LPG) in the complimented 
parasite cell line when compared to the wild type metacyclics of L. major [149].   
We also tested for the binding ability of the HDL to mutant surface. Our result shows that HDL binds to 
the metacyclics of WT as well as mutants WT L. major (Fig 27) suggesting that binding alone cannot 




A. In vitro TLF killing assay (L. major) 















D. In vivo 



























































































































































































Figure 26: Surface mutants are resistant to TLF activity 
A. Ficoll purified metacyclics of lpg5A-/lpg5B- or lpg5A-/lpg5B/+LPG5A+LPG5B were coincubated with 
lytic human HDL (TLF) or bovine HDL. N- Neutral for 2 hrs., A- 5.6 for 2 hrs., AA- 5.6 for 1 hr. followed 
by 4.5 for 1 hr., AP- 5.6 for 1 hour followed by 7.4 for 1 hr. Parasite numbers were determined by 
counting intact parasites under microscope using hemocytometer. The data represents Mean ± SD of 
duplicate cultures of one typical experiment that has been repeated twice, ns- non-significant 
compared to bovine HDL, ANOVA test. B. & C. Ficoll purified metacyclics of L. major (WT) or lpg5A-
/lpg5B or lpg5A-/lpg5B/+LPG5A+LPG5B were used to infect macrophages in the presence of human 
HDL or bovine HDL. Parasites were counted in macrophages at 24 hours post infection. The data *** 
p<0.0001, and ns- non significant, compared to bovine HDL, ANOVA test. D. Mice transfected with 
plasmid DNA with APOLI:HPR plasmid or Saline (control) were infected with lpg5A-/lpg5B- & lpg5A-
/lpg5B/+LPG5A+LPG5B in ear and parasite load were quantified by real time PCR 15 days post 
infection. The data represents Mean ± SD of one typical experiment repeated twice, ns- non-significant 
compared to control group, t-test. n = lpg5A-/lpg5B- : Saline (8), TLF (8); lpg5A-
/lpg5B/+LPG5A+LPG5B : Saline (6), TLF (8). E. Whole cell extracts of 2.5x105 metacyclic 
proamstigotes of wild type L. major or lpg5A-/lpg5B-/ +LPG5A+LPG5B were prepared using lysis 
buffer. The extract was then serially diluted to compare the expression of LPG proteins, which was 
probed using anti-phosphoglycan antibody WIC 79.3 [150]. 
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Figure 27: HDL binds to the metacyclics of both WT and mutants 
Labelled HDL was incubated with ficoll purified metacyclic of L. major (WT and lpg5A-/lpg5B-, lpg5A-
/lpg5B-/ +LPG5A+LPG5B). Fluorescence intensity was measured after washes using flow cytometer. 











Previously we have shown that TLF ameliorates the infection of cutaneous strains of Leishmania in 
macrophages and in mice [28]. Here we found that neutrophils act synergistically with TLF in reducing 
the parasite burden by L. major in mice (Fig 18). Given that TLF is an innate immunity factor that 
requires acidic pH for membrane association, we hypothesize that TLF associates with parasite 
membrane in the slightly acidic phagosome within the neutrophil; the TLF will eventually lyse 
metacyclic promastigotes due to change in pH when they are released into extracellular milieu or due 
to maturation of the phagosome to a fully acidified parasitophorus vacuole. In support of this 
hypothesis our in vitro results show that once TLF and the parasite come in contact with each other in 
an acidic media, the infectivity of the metacyclic parasites decreases upon neutralizing the parasite 
extracellular environment (Fig 19). Our result disputes the hypothesis “neutrophils are safe harbor for 
Leishmania sp.”, which is proposed based on depletion experiments in murine model. Although 
murines are useful model animals to study many biological phenomena, they are evolutionarily 
different than humans. Infact, previous studies have found some difference in behavior between 
mouse and human neutrophils. For example, murine neutrophil phagosomes with Leishmania are 
positive for ER markers suggesting that the phagosomes are of ER origin or they somehow interacts 
with ER after infection [120]. This phenomenon is not observed in human neutrophils infected with 
Leishmania sp. [151] Therefore, it is important to study the synergism between neutrophils and TLF 
using human neutrophils. 
Likewise, TLF rapidly lyses metacyclics when the parasites are co-incubated with TLF in slightly acidic 
media (pH 5.6) for 1 hour followed by further acidification (Fig 19). There is no detectable damage to 
metacyclic parasites co-incubated with bovine HDL under the same conditions. The co-incubation of 
the metacyclic parasites with lytic HDL (TLF) in neutral pH conditions also shows no detectable 
damage. These data taken together suggest that TLF requires an acidic pH for anti-metacyclic 
parasite activity. Furthermore, once associated with parasites in the acidic environment, TLF can 
damage parasites whether they go to the parasitophorous vacuole or egress from cells (Fig 28). The 
effect of TLF was complete lysis upon gradual acidification to pH 4.5 (parasitophorous vacuole). 
However, in macrophages or in mouse infections, we see some parasites always persisting 
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suggesting that not all parasites are exposed to low pH, or they occupy a phagosome devoid of TLF, 
or they have a mechanism to resist TLF. Previous studies have suggested that the LPG of metacyclic 
promastigotes of Leishmania sp. inhibits the fusion of lysosomes to phagosomes containing parasites 
thereby delaying the formation of PV and acidification [116, 117, 119]. This inhibition of phagosomal 
acidification may be the parasites’ way of evading TLF activity because TLF resistant amastigotes 
reside in acidic PV [118].  
 
Figure 28: Proposed Model for TLF mediated lysis of cutaneous Leishmania metacyclics 
Metacyclic promastigotes are phagocytosed by phagocytic cells such as neutrophils and 
macrophages. In the phagosomes, the TLF/APOL1 becomes integrated into  parasites surface 
membrane. Upon change of pH due to release of parasites from neutrophils or due to maturation of 
phagosomes to an acidic pahgolysosome, the parasites are lysed. 
 
Like amastigotes of L. amazonensis, metacyclics of visceral L. infantum and L. donovani are resistant 
to TLF activity (Fig. 19). Although both of the strains were resistant to TLF, we discovered that L. 
donovani infection would kill the host cells within 24 hours as measured by the release of Lactate 
dehydrogenase, a cytosolic enzyme of the infected macrophages (Fig. 21 C). The resistance to TLF 
by L. infantum does not require manipulation of the host environment by the parasites. We show that 
metacyclic promastigotes of L. infantum are resistant to lysis even when the parasites are incubated 
with TLF and subjected to acid priming or increasing acidification (Fig 22) suggesting that the visceral 
parasites are inherently resistant to TLF lysis. We observed similar resistance to TLF for the 
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amastigotes of L. amazonensis (Fig. 20). Under these conditions, lytic human HDL lyses the 
metacyclics of L. amazonensis suggesting that metacylic promastigotes of cutaneous strains are 
susceptible while amastigotes are resistant to TLF activity. This suggests that transformation to the 
dividing amastiogte stage limits the TLF activity against cutaneous strains such as L. major and L. 
amazonensis. This demonstrates the importance of TLF as an innate immunity factor in Leishmania 
infection.  
Finally, we have found that parasites deficient in golgi glycosylation enzymes that can not form 
phosphoglycan structure such as LPG and PPG were resistant to TLF activity (Fig. 26). We found 
lpg5A- /lpg5B- to be TLF resistant. This TLF resistance however, could not be restored in the 
complemented line lpg5A-/ lpg5B- /+LPG5A+LPG5B. We do not understand the reason for this 
discrepancy. It is possible that the glycosylation pattern of proteins govern the TLF susceptibility that is 
not restored completely in the add-back. In fact, we have found lower expression of LPG in the lpg5A-/ 
lpg5B- /+LPG5A+LPG5B as compared to the WT L. major (Fig 26 E), which could account for the 





Our results confirm that TLF is an important innate immunity factor in Leishmania infection that can 
govern the fate of infection. Our result shows that TLF has evolved as a host immune factor to kill 
parasite in intracellular environment. At the same time, the parasites have evolved to overcome the 
TLF activity and hence can eventually survive, divide and proliferate to cause disease pathogenesis. 
Therefore, there appears to be a molecular arms race between the host immunity factor TLF where 
the factor attempts to kill Leishmania sp. in immune cells such as macrophages and neutrophils. On 
the other hand the parasite evades this TLF mediated lysis by transforming into amastigotes with 





 Infantum in vivo      
Plate Well Sample 
Name 
Detector Ct  Ct Mean Ct SD Comments 
Plate1 A1 liver10^5 minicircleDNA 24.668 24.706 0.053  
Plate1 A2 liver10^5 minicircleDNA 24.743 24.706 0.053  
Plate1 A3 liver10^5 beta-cat 35.849 36.147 0.422  
Plate1 A4 liver10^5 beta-cat 36.446 36.147 0.422  
Plate1 B1 liver10^4 minicircleDNA 24.557 24.468 0.125 STD Curve 
Plate1 B2 liver10^4 minicircleDNA 24.380 24.468 0.125 
Plate1 B3 liver10^4 beta-cat 34.077 35.089 1.431 
Plate1 B4 liver10^4 beta-cat 36.101 35.089 1.431 
Plate1 C1 liver10^3 minicircleDNA 27.049 27.027 0.031 
Plate1 C2 liver10^3 minicircleDNA 27.005 27.027 0.031 
Plate1 C3 liver10^3 beta-cat 35.253 35.126 0.179 
Plate1 C4 liver10^3 beta-cat 34.999 35.126 0.179 
Plate1 D1 liver10^2 minicircleDNA 30.771 30.761 0.014 
Plate1 D2 liver10^2 minicircleDNA 30.751 30.761 0.014  
Plate1 D3 liver10^2 beta-cat 34.591 34.559 0.045  
Plate1 D4 liver10^2 beta-cat 34.528 34.559 0.045  
Plate1 E1 liver10^1 minicircleDNA 33.353 33.453 0.141  
Plate1 E2 liver10^1 minicircleDNA 33.553 33.453 0.141  
Plate1 E3 liver10^1 beta-cat 34.621 34.988 0.519  
Plate1 E4 liver10^1 beta-cat 35.356 34.988 0.519  
Plate1 A5 Saline 0 minicircleDNA 34.477 34.398 0.111 whole-30mg 
liver 
suspended 
Plate1 A6 Saline 0 minicircleDNA 34.320 34.398 0.111 
Plate1 A7 Saline 0 beta-cat 35.690 35.421 0.380 
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Plate1 A8 Saline 0 beta-cat 35.152 35.421 0.380 in 2ml trizol. 
50ul of the 
homogenate 
was used to 
obtain DNA. 




Plate1 B5 Saline 1 minicircleDNA 35.047 35.047 0.844 
Plate1 B6 Saline 1 minicircleDNA 35.047 35.047 0.844 
Plate1 B7 Saline 1 beta-cat 36.345 36.345 0.791 
Plate1 B8 Saline 1 beta-cat 36.345 36.345 0.791 
Plate1 C5 TLF 0 minicircleDNA 34.007 33.634 0.527 
Plate1 C6 TLF 0 minicircleDNA 33.262 33.634 0.527 
Plate1 C7 TLF 0 beta-cat 34.880 34.810 0.099 
Plate1 C8 TLF 0 beta-cat 34.740 34.810 0.099 
Plate1 D5 TLF 1 minicircleDNA 32.249 31.978 0.383 
Plate1 D6 TLF 1  minicircleDNA 31.707 31.978 0.383 
Plate1 D7 TLF 1 beta-cat 34.609 34.869 0.367 
Plate1 D8 TLF 1 beta-cat 35.128 34.869 0.367 
Plate1 E5 TLF 2 minicircleDNA 33.793 34.393 0.849 
Plate1 E6 TLF 2 minicircleDNA 34.994 34.393 0.849 
Plate1 E7 TLF 2 beta-cat 35.238 37.196 2.770  
Plate1 E8 TLF 2 beta-cat 39.155 37.196 2.770  
Plate1 F5 TLF 3 minicircleDNA 34.032 34.261 0.324  
Plate1 F6 TLF 3 minicircleDNA 34.490 34.261 0.324  
Plate1 F7 TLF 3 beta-cat Undeter
mined 
38.800   
Plate1 F8 TLF 3 beta-cat 38.800 38.800   
        
Plate 2 A1 liver10^5 minicircleDNA 24.615 24.699 0.119 Std Curve 
Plate 2 A2 liver10^5 minicircleDNA 24.783 24.699 0.119 
Plate 2 A3 liver10^5 beta-cat 36.304 36.802 0.703 
Plate 2 A4 liver10^5 beta-cat 37.299 36.802 0.703 
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Plate 2 B1 liver10^4 minicircleDNA 24.967 24.820 0.207 
Plate 2 B2 liver10^4 minicircleDNA 24.674 24.820 0.207  
Plate 2 B3 liver10^4 beta-cat 34.097 34.276 0.253  
Plate 2 B4 liver10^4 beta-cat 34.455 34.276 0.253  
Plate 2 C1 liver10^3 minicircleDNA 27.168 27.191 0.032  
Plate 2 C2 liver10^3 minicircleDNA 27.214 27.191 0.032  
Plate 2 C3 liver10^3 beta-cat 33.590 33.973 0.541  
Plate 2 C4 liver10^3 beta-cat 34.355 33.973 0.541  
Plate 2 D1 liver10^2 minicircleDNA 31.482 31.247 0.332  
Plate 2 D2 liver10^2 minicircleDNA 31.012 31.247 0.332  
Plate 2 D3 liver10^2 beta-cat 34.215 34.011 0.288  
Plate 2 D4 liver10^2 beta-cat 33.807 34.011 0.288  
Plate 2 E1 liver10^1 minicircleDNA 34.688 34.368 0.454  
Plate 2 E2 liver10^1 minicircleDNA 34.047 34.368 0.454  
Plate 2 E3 liver10^1 beta-cat 33.400 34.202 1.134  
Plate 2 E4 liver10^1 beta-cat 35.004 34.202 1.134  
Plate 2 A5 Saline 0 minicircleDNA 34.016 33.994 0.031 Remaining 
30 mg was 
suspended 
in 1ml trizol 







Plate 2 A6 Saline 0 minicircleDNA 33.972 33.994 0.031 
Plate 2 A7 Saline 0 beta-cat 34.645 34.472 0.245 
Plate 2 A8 Saline 0 beta-cat 34.298 34.472 0.245 
Plate 2 B5 Saline 1 minicircleDNA 31.433 31.331 0.144 
Plate 2 B6 Saline 1 minicircleDNA 31.229 31.331 0.144 
Plate 2 B7 Saline 1 beta-cat 34.518 34.450 0.097 
Plate 2 B8 Saline 1 beta-cat 34.381 34.450 0.097 
Plate 2 C5 Saline 2 minicircleDNA 34.582 34.896 0.444 
Plate 2 C6 Saline 2 minicircleDNA 35.210 34.896 0.444 




Plate 2 C8 Saline 2 beta-cat 34.809 35.366 0.788  
Plate 2 D5 TLF0 minicircleDNA 34.142 34.652 0.721  
Plate 2 D6 TLF0 minicircleDNA 35.163 34.652 0.721  
Plate 2 D7 TLF0 beta-cat 35.409 35.902 0.698  
Plate 2 D8 TLF0 beta-cat 36.396 35.902 0.698  
Plate 2 E5 TLF1 minicircleDNA 33.981 34.075 0.133  
Plate 2 E6 TLF1 minicircleDNA 34.168 34.075 0.133  
Plate 2 E7 TLF1 beta-cat 33.395 33.076 0.450  
Plate 2 E8 TLF1 beta-cat 32.758 33.076 0.450  
Plate 2 F5 TLF2 minicircleDNA 34.284 34.193 0.129  
Plate 2 F6 TLF2 minicircleDNA 34.102 34.193 0.129  
Plate 2 F7 TLF2 beta-cat 33.417 33.559 0.201  
Plate 2 F8 TLF2 beta-cat 33.701 33.559 0.201  
Plate 2 G5 TLF3 minicircleDNA 32.515 33.121 0.857  
Plate 2 G6 TLF3 minicircleDNA 33.727 33.121 0.857  
Plate 2 G7 TLF3 beta-cat 34.302 34.920 0.874  
Plate 2 G8 TLF3 beta-cat 35.538 34.920 0.874  
        
        
 Neutrophil 
depletion 
     
Plate1 A1 EAR10^5 minicircleDNA 22.330  0.162  
Plate1 A2 EAR10^5 minicircleDNA 22.558  0.162  
Plate1 A3 EAR10^5 beta-cat 29.323  0.089  
Plate1 A4 EAR10^5 beta-cat 29.449  0.089  
Plate1 B1 EAR10^4 minicircleDNA 24.623  0.311 STD Curve 
Plate1 B2 EAR10^4 minicircleDNA 24.184  0.311 
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Plate1 B3 EAR10^4 beta-cat 28.795  0.020 
Plate1 B4 EAR10^4 beta-cat 28.823  0.020 
Plate1 C1 EAR10^3 minicircleDNA 28.043  0.037 
Plate1 C2 EAR10^3 minicircleDNA 27.990  0.037 
Plate1 C3 EAR10^3 beta-cat 28.784  0.102 
Plate1 C4 EAR10^3 beta-cat 28.928  0.102 
Plate1 D1 EAR10^2 minicircleDNA 31.881  0.113  
Plate1 D2 EAR10^2 minicircleDNA 31.721  0.113  
Plate1 D3 EAR10^2 beta-cat 29.662  0.101  
Plate1 D4 EAR10^2 beta-cat 29.519  0.101  
Plate1 E1 EAR10^1 minicircleDNA 34.609  0.752  
Plate1 E2 EAR10^1 minicircleDNA 33.546  0.752  
Plate1 E3 EAR10^1 beta-cat 29.748  0.388  
Plate1 E4 EAR10^1 beta-cat 30.296  0.388  
Plate1 F1 EAR ONLY minicircleDNA 35.119  0.388  
Plate1 F2 EAR ONLY minicircleDNA 34.571  0.388  
Plate1 F3 EAR ONLY beta-cat 28.938  0.161  
Plate1 F4 EAR ONLY beta-cat 29.166  0.161  
        
Plate2 F1 Saline/Isot
ype 
minicircleDNA 33.215 33.042 0.245  
Plate2 F2 Saline/Isot
ype 
minicircleDNA 32.869 33.042 0.245  
Plate2 F3 Saline/Isot
ype 










minicircleDNA 31.998 32.113 0.164 Ear 
resuspende


















beta-cat 38.272 38.272  
Plate2 G1 Saline/Isot
ype 
minicircleDNA 31.685 31.611 0.104 
Plate2 G2 Saline/Isot
ype 
minicircleDNA 31.538 31.611 0.104 
Plate2 G3 Saline/Isot
ype 
beta-cat 37.049 37.539 0.692 
Plate2 G4 Saline/Isot
ype 
beta-cat 38.028 37.539 0.692 
Plate2 G5 Saline/Isot
ype 
minicircleDNA 31.713 31.805 0.130 
Plate2 G6 Saline/Isot
ype 





38.718   
Plate2 G8 Saline/Isot
ype 
beta-cat 38.718 38.718   
Plate2 A1 TLF/Isotyp
e 
minicircleDNA 32.993 33.268 0.389  






beta-cat 37.353 37.883 0.750  
Plate2 A4 TLF/Isotyp
e 
beta-cat 38.414 37.883 0.750  
Plate2 A5 TLF/Isotyp
e 
minicircleDNA 35.312 35.498 0.263  
Plate2 A6 TLF/Isotyp
e 
minicircleDNA 35.684 35.498 0.263  
Plate2 A7 TLF/Isotyp
e 





36.463   
Plate2 B1 TLF/Isotyp
e 
minicircleDNA 32.426 32.406 0.027  
Plate2 B2 TLF/Isotyp
e 
minicircleDNA 32.387 32.406 0.027  
Plate2 B3 TLF/Isotyp
e 
beta-cat 33.236 33.325 0.126  
Plate2 B4 TLF/Isotyp
e 
beta-cat 33.414 33.325 0.126  
Plate2 B5 TLF/Isotyp
e 
minicircleDNA 34.166 33.965 0.283  
Plate2 B6 TLF/Isotyp
e 
minicircleDNA 33.765 33.965 0.283  
Plate2 B7 TLF/Isotyp
e 





beta-cat 36.667 36.781 0.162  
Plate2 C1 TLF/1A8 minicircleDNA 32.103 31.944 0.225  
Plate2 C2 TLF/1A8 minicircleDNA 31.785 31.944 0.225  
Plate2 C3 TLF/1A8 beta-cat 39.228 38.464 1.080  
Plate2 C4 TLF/1A8 beta-cat 37.700 38.464 1.080  
Plate2 C5 TLF/1A8 minicircleDNA 33.140 33.348 0.295  
Plate2 C6 TLF/1A8 minicircleDNA 33.557 33.348 0.295  
Plate2 C7 TLF/1A8 beta-cat 39.228 38.464 1.080  
Plate2 C8 TLF/1A8 beta-cat 37.700 38.464 1.080  
Plate2 H1 TLF/1A8 minicircleDNA 32.726 32.742 0.023  
Plate2 H2 TLF/1A8 minicircleDNA 32.758 32.742 0.023  
Plate2 H3 TLF/1A8 beta-cat Undeter
mined 
38.401   
Plate2 H4 TLF/1A8 beta-cat 38.401 38.401   
Plate2 H5 TLF/1A8 minicircleDNA 33.100 32.793 0.435  
Plate2 H6 TLF/1A8 minicircleDNA 32.486 32.793 0.435  
Plate2 H7 TLF/1A8 beta-cat 39.216 38.458 1.072  
Plate2 H8 TLF/1A8 beta-cat 37.700 38.458 1.072  
Plate2 E1 Saline/1A8 minicircleDNA 32.532 32.617 0.121  
Plate2 E2 Saline/1A8 minicircleDNA 32.703 32.617 0.121  
Plate2 E3 Saline/1A8 beta-cat 37.181 37.750 0.804  
Plate2 E4 Saline/1A8 beta-cat 38.318 37.750 0.804  
Plate2 E5 Saline/1A8 minicircleDNA 33.699 34.127 0.606  
Plate2 E6 Saline/1A8 minicircleDNA 34.556 34.127 0.606  
Plate2 E7 Saline/1A8 beta-cat 37.750 37.750   




Plate2 D1 Saline/1A8 minicircleDNA 29.810 29.958 0.210  
Plate2 D2 Saline/1A8 minicircleDNA 30.106 29.958 0.210  
Plate2 D3 Saline/1A8 beta-cat 33.781 34.514 1.037  
Plate2 D4 Saline/1A8 beta-cat 35.248 34.514 1.037  
Plate2 D5 Saline/1A8 minicircleDNA 34.892 34.702 0.268  
Plate2 D6 Saline/1A8 minicircleDNA 34.513 34.702 0.268  
Plate2 D7 Saline/1A8 beta-cat Undeter
mined 
39.864   
Plate2 D8 Saline/1A8 beta-cat 39.864 39.864   
        
LPG5 
experiment 
      
 A1 EAR10^6 minicircleDNA 22.109 22.148 0.056  
 A2 EAR10^6 minicircleDNA 22.188 22.148 0.056  
 A3 EAR10^6 beta-cat 30.049 30.094 0.064  
 A4 EAR10^6 beta-cat 30.139 30.094 0.064  
 B1 EAR10^5 minicircleDNA 25.318 25.295 0.033  
 B2 EAR10^5 minicircleDNA 25.272 25.295 0.033  






 B4 EAR10^5 beta-cat 31.103 31.217 0.161 
 C1 EAR10^4 minicircleDNA 29.166 29.380 0.302 
 C2 EAR10^4 minicircleDNA 29.593 29.380 0.302 
 C3 EAR10^4 beta-cat 31.787 31.953 0.235 
 C4 EAR10^4 beta-cat 32.120 31.953 0.235 
 D1 EAR10^3 minicircleDNA 29.315 29.324 0.013  
 D2 EAR10^3 minicircleDNA 29.333 29.324 0.013  
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 D3 EAR10^3 beta-cat 31.915 31.633 0.398  
 D4 EAR10^3 beta-cat 31.351 31.633 0.398  
 E1 EAR10^2 minicircleDNA 30.403 30.540 0.195  
 E2 EAR10^2 minicircleDNA 30.678 30.540 0.195  
 E3 EAR10^2 beta-cat 31.995 32.062 0.095  
 E4 EAR10^2 beta-cat 32.129 32.062 0.095  
lpg5A-/lpg5b-       
Plate1 A9 TLF1 minicircleDNA 30.886 30.909 0.032  
Plate1 A10 TLF1 minicircleDNA 30.931 30.909 0.032  
Plate1 A11 TLF1 beta-cat 34.655 35.056 0.567  
Plate1 A12 TLF1 beta-cat 35.456 35.056 0.567  
Plate1 B9 TLF2 minicircleDNA 30.550 30.615 0.092  
Plate1 B10 TLF2 minicircleDNA 30.680 30.615 0.092  
Plate1 B11 TLF2 beta-cat 33.782 33.808 0.036  
Plate1 B12 TLF2 beta-cat 33.834 33.808 0.036  
Plate1 C9 TLF3 minicircleDNA 30.095 29.979 0.165  
Plate1 C10 TLF3 minicircleDNA 29.862 29.979 0.165  
Plate1 C11 TLF3 beta-cat 35.196 35.194 0.004  
Plate1 C12 TLF3 beta-cat 35.191 35.194 0.004  
Plate1 D9 TLF4 minicircleDNA 30.528 30.591 0.089  
Plate1 D10 TLF4 minicircleDNA 30.654 30.591 0.089  
Plate1 D11 TLF4 beta-cat 35.533 35.335 0.281  
Plate1 D12 TLF4 beta-cat 35.136 35.335 0.281  
Plate1 E9 TLF5 minicircleDNA 31.251 31.074 0.250  
Plate1 E10 TLF5 minicircleDNA 30.897 31.074 0.250  
Plate1 E11 TLF5 beta-cat 35.258 35.325 0.095  
Plate1 E12 TLF5 beta-cat 35.392 35.325 0.095  
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Plate1 F9 TLF6 minicircleDNA 30.828 30.879 0.073  
Plate1 F10 TLF6 minicircleDNA 30.930 30.879 0.073  
Plate1 F11 TLF6 beta-cat 31.800 32.240 0.622  
Plate1 F12 TLF6 beta-cat 32.679 32.240 0.622  
Plate1 G5 TLF7 minicircleDNA 32.092 31.954 0.195  
Plate1 G6 TLF7 minicircleDNA 31.817 31.954 0.195  
Plate1 G7 TLF7 beta-cat 33.473 33.879 0.574  
Plate1 G8 TLF7 beta-cat 34.285 33.879 0.574  
Plate1 H5 TLF8 minicircleDNA 32.114 31.969 0.205  
Plate1 H6 TLF8 minicircleDNA 31.825 31.969 0.205  
Plate1 H7 TLF8 beta-cat 33.088 33.435 0.490  
Plate1 H8 TLF8 beta-cat 33.781 33.435 0.490  
Plate2 C5 Saline1 minicircleDNA 31.597 31.465 0.187  
Plate2 C6 Saline1 minicircleDNA 31.333 31.465 0.187  
Plate2 C7 Saline1 beta-cat 33.874 34.142 0.380  
Plate2 C8 Saline1 beta-cat 34.411 34.142 0.380  
Plate2 D5 Saline 2 minicircleDNA 30.751 30.909 0.223  
Plate2 D6 Saline 2 minicircleDNA 31.066 30.909 0.223  
Plate2 D7 Saline 2 beta-cat 32.472 32.432 0.057  
Plate2 D8 Saline 2 beta-cat 32.392 32.432 0.057  
Plate2 E5 Saline 3 minicircleDNA 31.992 32.197 0.290  
Plate2 E6 Saline 3 minicircleDNA 32.403 32.197 0.290  
Plate2 E7 Saline 3 beta-cat 34.915 35.642 1.027  
Plate2 E8 Saline 3 beta-cat 36.368 35.642 1.027  
Plate2 F5 Saline 4 minicircleDNA 31.745 31.627 0.167  
Plate2 F6 Saline 4 minicircleDNA 31.508 31.627 0.167  
Plate2 F7 Saline 4 beta-cat 32.808 32.976 0.237  
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Plate2 F8 Saline 4 beta-cat 33.144 32.976 0.237  
Plate2 G5 Saline5 minicircleDNA 31.093 31.204 0.157  
Plate2 G6 Saline5 minicircleDNA 31.315 31.204 0.157  
Plate2 G7 Saline5 beta-cat 33.371 34.099 1.029  
Plate2 G8 Saline5 beta-cat 34.827 34.099 1.029  
Plate2 H5 Saline 6 minicircleDNA 30.400 30.404 0.005  
Plate2 H6 Saline 6 minicircleDNA 30.407 30.404 0.005  
Plate2 H7 Saline 6 beta-cat 31.949 32.098 0.212  
Plate2 H8 Saline 6 beta-cat 32.248 32.098 0.212  
        
lpg5-A-/lpg5B-
/+LPG5A+LPG5B 
     
Plate 1 A5 TLF1 minicircleDNA 31.687 31.701 0.019  
Plate 1 A6 TLF1 minicircleDNA 31.715 31.701 0.019  
Plate 1 A7 TLF1 beta-cat 34.300 34.031 0.380  
Plate 1 A8 TLF1 beta-cat 33.762 34.031 0.380  
Plate 1 B5 TLF2 minicircleDNA 30.775 30.807 0.046  
Plate 1 B6 TLF2 minicircleDNA 30.840 30.807 0.046  
Plate 1 B7 TLF2 beta-cat 31.488 31.810 0.455  
Plate 1 B8 TLF2 beta-cat 32.132 31.810 0.455  
Plate 1 C5 TLF3 minicircleDNA 31.150 31.183 0.046  
Plate 1 C6 TLF3 minicircleDNA 31.215 31.183 0.046  
Plate 1 C7 TLF3 beta-cat 33.257 33.286 0.041  
Plate 1 C8 TLF3 beta-cat 33.315 33.286 0.041  
Plate 1 D5 TLF4 minicircleDNA 30.915 30.956 0.057  
Plate 1 D6 TLF4 minicircleDNA 30.996 30.956 0.057  
Plate 1 D7 TLF4 beta-cat 32.217 31.966 0.354  
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Plate 1 D8 TLF4 beta-cat 31.716 31.966 0.354  
Plate 1 E5 TLF5 minicircleDNA 30.939 31.127 0.267  
Plate 1 E6 TLF5 minicircleDNA 31.316 31.127 0.267  
Plate 1 E7 TLF5 beta-cat 33.343 33.314 0.041  
Plate 1 E8 TLF5 beta-cat 33.286 33.314 0.041  
Plate 1 F5 TLF6 minicircleDNA 32.151 32.059 0.130  
Plate 1 F6 TLF6 minicircleDNA 31.967 32.059 0.130  
Plate 1 F7 TLF6 beta-cat 34.870 34.821 0.069  
Plate 1 F8 TLF6 beta-cat 34.772 34.821 0.069  
Plate 1 G5 TLF7 minicircleDNA 32.092 31.954 0.195  
Plate 1 G6 TLF7 minicircleDNA 31.817 31.954 0.195  
Plate 1 G7 TLF7 beta-cat 33.473 33.879 0.574  
Plate 1 G8 TLF7 beta-cat 34.285 33.879 0.574  
Plate 1 H5 TLF8 minicircleDNA 32.114 31.969 0.205  
Plate 1 H6 TLF8 minicircleDNA 31.825 31.969 0.205  
Plate 1 H7 TLF8 beta-cat 33.088 33.435 0.490  
Plate 1 H8 TLF8 beta-cat 33.781 33.435 0.490  
Plate 2 C9 Saline1 minicircleDNA 31.688 32.135 0.632  
Plate 2 C10 Saline1 minicircleDNA 32.582 32.135 0.632  
Plate 2 C11 Saline1 beta-cat 34.300 33.736 0.798  
Plate 2 C12 Saline1 beta-cat 33.172 33.736 0.798  
Plate 2 D9 Saline 2 minicircleDNA 31.407 31.521 0.161  
Plate 2 D10 Saline 2 minicircleDNA 31.635 31.521 0.161  
Plate 2 D11 Saline 2 beta-cat 31.157 31.407 0.354  
Plate 2 D12 Saline 2 beta-cat 31.658 31.407 0.354  
Plate 2 E9 Saline3 minicircleDNA 31.816 32.050 0.331  
Plate 2 E10 Saline3 minicircleDNA 32.283 32.050 0.331  
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Plate 2 E11 Saline3 beta-cat 32.319 32.682 0.513  
Plate 2 E12 Saline3 beta-cat 33.045 32.682 0.513  
Plate 2 F9 Saline4 minicircleDNA 31.773 31.678 0.134  
Plate 2 F10 Saline4 minicircleDNA 31.584 31.678 0.134  
Plate 2 F11 Saline4 beta-cat 32.248 32.093 0.219  
Plate 2 F12 Saline4 beta-cat 31.938 32.093 0.219  
Plate 2 G9 Saline5 minicircleDNA 32.588 32.421 0.236  
Plate 2 G10 Saline5 minicircleDNA 32.254 32.421 0.236  
Plate 2 G11 Saline5 beta-cat 32.554 32.281 0.386  
Plate 2 G12 Saline5 beta-cat 32.008 32.281 0.386  
Plate 2 H9 Saline6 minicircleDNA 32.748 32.549 0.282  
Plate 2 H10 Saline6 minicircleDNA 32.349 32.549 0.282  
Plate 2 H11 Saline6 beta-cat 34.317 34.817 0.708  
Plate 2 H12 Saline6 beta-cat 35.318 34.817 0.708  
Plate 2 A5 Saline7 minicircleDNA 27.372 27.357 0.021  
Plate 2 A6 Saline7 minicircleDNA 27.343 27.357 0.021  
Plate 2 A7 Saline7 beta-cat 33.231 33.821 0.835  
Plate 2 A8 Saline7 beta-cat 34.412 33.821 0.835  
Plate 2 B5 Saline 8 minicircleDNA 26.598 26.617 0.026  
Plate 2 B6 Saline 8 minicircleDNA 26.636 26.617 0.026  
Plate 2 B7 Saline 8 beta-cat 33.172 33.265 0.132  
Plate 2 B8 Saline 8 beta-cat 33.359 33.265 0.132  
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